Manal F. Abdelmalek
Professor of Medicine
My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.
Current Appointments & Affiliations
- Professor of Medicine, Medicine, Gastroenterology, Medicine 2017
Contact Information
- 03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
- Duke Box 3913, Durham, NC 27710
-
manal.abdelmalek@duke.edu
(919) 684-3262
- Background
-
Education, Training, & Certifications
- Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences 1995 - 1998
- Medical Resident, Medicine, Mayo School of Health Sciences 1992 - 1995
- M.D., University of Missouri Kansas City, School of Medicine 1992
-
Duke Appointment History
- Associate Professor of Medicine, Medicine, Gastroenterology, Medicine 2014 - 2017
- Associate Professor of Medicine, Medicine, Gastroenterology, Medicine 2006 - 2014
- Instructor, Temporary in the Department of Medicine, Medicine, Gastroenterology, Medicine 2006
- Research
-
Selected Grants
- Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (ALPINE 4) awarded by NGM Biopharmaceuticals, Inc. 2020 - 2024
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH awarded by Hanmi Pharmaceutical 2020 - 2024
- TERN101-201 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients awarded by SC Liver Research Consortium, LLC 2020 - 2024
- A multidisciplinary study of biological disparities in NASH progression and response to statins to inform personalized liver cancer chemoprevention in NAFLD awarded by Department of Defense 2020 - 2024
- A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation awarded by Madrigal Pharmaceuticals, Inc. 2019 - 2024
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) awarded by National Institutes of Health 2004 - 2024
- A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1) awarded by Madrigal Pharmaceuticals, Inc. 2020 - 2024
- ARMOR awarded by Galmed Pharmaceuticals Ltd. 2019 - 2023
- Celgene CC-90001 NASH-001 awarded by Celgene Corporation 2019 - 2023
- Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis awarded by Novo Nordisk A/S 2019 - 2023
- Duke CTSA (TL1) awarded by National Institutes of Health 2018 - 2023
- VK2809 A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoholic awarded by Viking Therapeutics, Inc. 2020 - 2023
- A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis. awarded by TARGET PharmaSolutions, Inc. 2017 - 2023
- Is Heart Failure with Preserved Edection Fraction the Symptomatic Manifestation of Liver Disease awarded by American Heart Association 2021 - 2022
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) awarded by AstraZeneca Pharmaceuticals, LP 2020 - 2022
- Intercept 747-303 - A phase 3 double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of Obeticholic acid in subjects with Nonalcoholic Steatohepatitis. awarded by Intercept Pharmaceuticals, Inc 2015 - 2022
- Genentech GC41003 awarded by Genentech, Inc. 2019 - 2022
- A Randomized, Open-label, Phase 1b Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Signals of DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH) awarded by DURECT Corporation 2019 - 2022
- A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in adults with nonalcoholic steatohepatitis (NASH) and Compensated Liver Cirrhosis awarded by Bristol-Myers Squibb Company 2018 - 2022
- A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in adults with nonalcoholic steatohepatitis (NASH) and Stage 3 liver fibrosis awarded by Bristol-Myers Squibb Company 2018 - 2022
- Inventiva IVA337 awarded by Inventiva 2019 - 2022
- NGM282 18-0108 awarded by NGM Biopharmaceuticals, Inc. 2019 - 2022
- A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis awarded by ENYO Pharma SA 2019 - 2022
- Genfit GFT505-315-1 NASH - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy adn Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis. awarded by GENFIT 2016 - 2022
- A randomized, double-blind, placebo-controlled, parallel group trial to assess the efficacy and safety of PXL770 versus placebo after 12 weeks of treatment in patients with Nonalcoholic Fatty Liver Disease (NAFLD) with or without type 2 diabetes awarded by Poxel S.A. 2019 - 2021
- Novartis LJC242A2201J awarded by Novartis Pharmaceuticals Corporation 2018 - 2021
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis awarded by Intercept Pharmaceuticals, Inc 2017 - 2021
- Ancillary Studies of NAFLD and NASH in HIV infected Adults awarded by Indiana University 2020 - 2021
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis awarded by Allergan, Inc. 2017 - 2020
- Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) awarded by Allergan, Inc. 2017 - 2020
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) awarded by Gilead Sciences, Inc. 2017 - 2020
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis awarded by Gilead Sciences, Inc. 2017 - 2020
- Progenity PRO-121-NAFLD - EVALUATION OF THE SIGNIFICANCE OF CELL FREE DNA AND EPIGENETIC MARKERS AS PREDICTIVE FACTORS FOR NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) awarded by Progenity, Inc. 2017 - 2020
- A Phase 2 Dose Ranging, Randomized Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohepatitis (NASH) EDP 305-101 awarded by Enanta Pharmaceuticals, Inc. 2018 - 2020
- Gilead 454-4378 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to NASH awarded by Gilead Sciences, Inc. 2018 - 2020
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis awarded by Conatus Pharmaceuticals 2017 - 2020
- Galectin GI-026 A Multi-Center, Randomized, Controlled, Double-blind, Parallel Group, Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH awarded by Galectin Therapeutics, Inc. 2015 - 2020
- Genetic and Epigenetic Markers of Progressive Nonalcoholic Fatty Liver Disease awarded by American Association for the Study of Liver Diseases 2018 - 2020
- Gilead 384-1497 A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 alone or in Combination with Simtuzumab (SIM) in Subjects with Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3. awarded by Gilead Sciences, Inc. 2015 - 2020
- A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2017 - 2020
- Conatus IDN 6556-14 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Porta awarded by Conatus Pharmaceuticals 2016 - 2019
- TOBIRA 652-2-203 awarded by Tobira Therapeutics, Inc 2014 - 2019
- Madrigal MGL-3196-05 A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis awarded by Madrigal Pharmaceuticals, Inc. 2016 - 2019
- Conatus IDN-6556-12 A Multicenter, Randomized, Double-Blind, Placebo controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis awarded by Conatus Pharmaceuticals 2015 - 2019
- A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatit awarded by NGM Biopharmaceuticals 2015 - 2019
- BMS MB130-045 awarded by Bristol-Myers Squibb Company 2015 - 2019
- Immuron IMM-124E A phase II, randomized, double-blind, placebo-controlled study of IMM-124E for patients with non-alcoholic steatohepatitis. awarded by Immuron, Ltd 2014 - 2019
- Shire SHP626-201...A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with awarded by Shire Human Genetics Therapies 2016 - 2019
- Gilead 402-1852 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS 9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) awarded by Gilead Sciences, Inc. 2016 - 2019
- GILEAD 426-3989 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects with Nonalcoholic Steatohepatitis awarded by Gilead Sciences, Inc. 2016 - 2019
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis with Fibrosis awarded by Intercept Pharmaceuticals, Inc 2018 - 2019
- A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH) awarded by Galmed Pharmaceuticals Ltd. 2015 - 2019
- Intercept 747-209 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects with Nonalcoholic Steatohepatitis awarded by Intercept Pharmaceuticals, Inc 2015 - 2019
- Cirius EMMINENCE awarded by Cirius Therapeutics 2017 - 2018
- Exalenz - CSPH-EX-0414 Clinical Study of the BreathID® LF System to train the algorithm for the ¹³C-Methacetin Breath Test (MBT) in assessment of Portal Hypertension in Patients with Compensated Liver Cirrhosis awarded by Exalenz Bioscience Ltd. 2016 - 2018
- To evaluate how protease expression changes throughout the course of NASH. awarded by Glympse Bio, Inc. 2017
- Acoustic Radiation Force Based Hepatic Elasticity Quantification and Imaging awarded by National Institutes of Health 2001 - 2017
- ARI-3037MO-006 A RANDOMIZED, DOUBLE-BLIND, EXPLORATORY PHASE 2 STUDY TO ASSESS THE EFFECTS OF ARI¿3037MO ON HEPATIC FAT METABOLISM IN PATIENTS WITH DYSGLYCEMIA AND EVIDENCE OF HEPATIC STEATOSIS WITH NONALCOHOLIC FATTY LIVER DISEASE OR NONALCOHOLIC ST awarded by Arisaph Pharmaceuticals, Inc. 2015 - 2017
- Impact of Fructose on Metabolism, Energy Homeostasis and MR biomarkers in NAFLD awarded by National Institutes of Health 2012 - 2016
- Synageva BioPharma LAL-CSS01 A STUDY TO IDENTIFY THE FREQUENCY OF LYSOSOMAL ACID LIPASE DEFICIENCY IN AT-RISK PATIENT POPULATIONS awarded by Synageva BioPharma 2014 - 2016
- Development and clinical validation of a clinical diagnostic/prognostic laboratory test for liver disease awarded by Metabolon, Inc. 2014 - 2016
- Characterizing Alcohol's Effects on Repair of Liver Injury awarded by National Institutes of Health 2009 - 2012
- Hyperinsulimia and Insulin Resistance in Nonalcoholic Fatty Liver Disease awarded by National Institutes of Health 2006 - 2010
-
External Relationships
- Allergan
- Bristol-Myers Squibb
- Celgene Pharmaceuticals
- Clinical Care Options
- Durect
- Galmed
- Galmed
- Genentech, Inc (Roche Holding)
- Genfit
- Hamni Pharmaceuticals
- Intercept
- Inventiva
- Madrigal
- NGM Biopharmaceuticals
- Novo Nordisk
- PanNASH Initiative
- Poxel
- Prime Education
- Promethera Biosciences
- Taiwan J Pharmaceuticals
- iHEP NASH
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Peters, Anthony E., Ambarish Pandey, Colby Ayers, Kara Wegermann, Robert W. McGarrah, Justin L. Grodin, Manal F. Abdelmalek, et al. “Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT.” Esc Heart Fail, February 14, 2021. https://doi.org/10.1002/ehf2.13250.Full Text Link to Item
-
Abdelmalek, Manal F. “Nonalcoholic fatty liver disease: another leap forward.” Nat Rev Gastroenterol Hepatol 18, no. 2 (February 2021): 85–86. https://doi.org/10.1038/s41575-020-00406-0.Full Text Link to Item
-
Frenette, Catherine, Zeid Kayali, Edward Mena, Parvez S. Mantry, Kathryn J. Lucas, Guy Neff, Miguel Rodriguez, et al. “Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.” J Hepatol 74, no. 2 (February 2021): 274–82. https://doi.org/10.1016/j.jhep.2020.09.029.Full Text Link to Item
-
Francque, Sven, Gyongyi Szabo, Manal F. Abdelmalek, Christopher D. Byrne, Kenneth Cusi, Jean-François Dufour, Michael Roden, Frank Sacks, and Frank Tacke. “Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.” Nat Rev Gastroenterol Hepatol 18, no. 1 (January 2021): 24–39. https://doi.org/10.1038/s41575-020-00366-5.Full Text Link to Item
-
Spiritos, Zachary, and Manal F. Abdelmalek. “Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis.” Transl Gastroenterol Hepatol 6 (2021): 13. https://doi.org/10.21037/tgh.2020.02.07.Full Text Link to Item
-
White, Phillip J., and Manal F. Abdelmalek. “Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH.” Clin Liver Dis (Hoboken) 17, no. 1 (January 2021): 29–32. https://doi.org/10.1002/cld.1062.Full Text Link to Item
-
Loomba, Rohit, Brent A. Neuschwander-Tetri, Arun Sanyal, Naga Chalasani, Anna Mae Diehl, Norah Terrault, Kris Kowdley, et al. “Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.” Hepatology 72, no. 4 (October 2020): 1219–29. https://doi.org/10.1002/hep.31121.Full Text Link to Item
-
Glass, Oliver, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, et al. “Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.” J Hepatol 73, no. 3 (September 2020): 680–93. https://doi.org/10.1016/j.jhep.2020.04.030.Full Text Link to Item
-
Wegermann, Kara, Ayako Suzuki, Alisha M. Mavis, Manal F. Abdelmalek, Anna Mae Diehl, and Cynthia A. Moylan. “Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.” Hepatology, August 31, 2020. https://doi.org/10.1002/hep.31533.Full Text Link to Item
-
Eslam, Mohammed, Arun J. Sanyal, Jacob George, and Jacob International Consensus Panel. “MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.” Gastroenterology 158, no. 7 (May 2020): 1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.Full Text Link to Item
-
Garcia-Tsao, Guadalupe, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, et al. “Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.” J Hepatol 72, no. 5 (May 2020): 885–95. https://doi.org/10.1016/j.jhep.2019.12.010.Full Text Link to Item
-
Chalasani, Naga, Manal F. Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary Rinella, Mazen Noureddin, et al. “Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.” Gastroenterology 158, no. 5 (April 2020): 1334-1345.e5. https://doi.org/10.1053/j.gastro.2019.11.296.Full Text Link to Item
-
Liu, Xue-Jing, Li Xie, Kuo Du, Chang Liu, Ning-Ping Zhang, Chen-Jian Gu, Ying Wang, et al. “Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation.” Liver Int 40, no. 4 (April 2020): 830–43. https://doi.org/10.1111/liv.14370.Full Text Link to Item
-
Anstee, Quentin M., Brent A. Neuschwander-Tetri, Vincent Wai-Sun Wong, Manal F. Abdelmalek, Zobair M. Younossi, Jiacheng Yuan, Maria Lucia Pecoraro, et al. “Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.” Contemp Clin Trials 89 (February 2020): 105922. https://doi.org/10.1016/j.cct.2019.105922.Full Text Link to Item
-
Du, Kuo, Satish K. Chitneni, Ayako Suzuki, Ying Wang, Ricardo Henao, Jeongeun Hyun, Richard T. Premont, et al. “Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.” Cell Mol Gastroenterol Hepatol 10, no. 1 (2020): 1–21. https://doi.org/10.1016/j.jcmgh.2019.12.006.Full Text Link to Item
-
Siddiqui, Mohammad Shadab, Mark L. Van Natta, Margery A. Connelly, Raj Vuppalanchi, Brent A. Neuschwander-Tetri, James Tonascia, Cynthia Guy, et al. “Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.” J Hepatol 72, no. 1 (January 2020): 25–33. https://doi.org/10.1016/j.jhep.2019.10.006.Full Text Link to Item
-
Sanyal, Arun, Edgar D. Charles, Brent A. Neuschwander-Tetri, Rohit Loomba, Stephen A. Harrison, Manal F. Abdelmalek, Eric J. Lawitz, et al. “Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.” Lancet 392, no. 10165 (December 22, 2019): 2705–17. https://doi.org/10.1016/S0140-6736(18)31785-9.Full Text Link to Item
-
Younossi, Zobair M., Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M. Anstee, Zachary Goodman, Pierre Bedossa, et al. “Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.” Lancet 394, no. 10215 (December 14, 2019): 2184–96. https://doi.org/10.1016/S0140-6736(19)33041-7.Full Text Link to Item
-
Win, Sanda, Robert Wm Min, Christopher Q. Chen, Jun Zhang, Yibu Chen, Meng Li, Ayako Suzuki, et al. “Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury.” J Clin Invest 129, no. 12 (December 2, 2019): 5278–93. https://doi.org/10.1172/JCI128289.Full Text Link to Item
-
Gawrieh, Samer, Xiuqing Guo, Jingyi Tan, Marie Lauzon, Kent D. Taylor, Rohit Loomba, Oscar W. Cummings, et al. “A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH.” Hepatol Commun 3, no. 12 (December 2019): 1571–84. https://doi.org/10.1002/hep4.1439.Full Text Link to Item
-
Samji, Naga Swetha, Rajanshu Verma, Krishna Chaitanya Keri, Ashwani K. Singal, Aijaz Ahmed, Mary Rinella, David Bernstein, Manal F. Abdelmalek, and Sanjaya K. Satapathy. “Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.” Dig Dis Sci 64, no. 12 (December 2019): 3413–30. https://doi.org/10.1007/s10620-019-05716-1.Full Text Link to Item
-
Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, et al. “The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.” Hepatology 70, no. 6 (December 2019): 1913–27. https://doi.org/10.1002/hep.30664.Full Text Link to Item
-
Rana, Rajashree, Andrew M. Shearer, Elizabeth K. Fletcher, Nga Nguyen, Srijoy Guha, Daniel H. Cox, Manal Abdelmalek, et al. “PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease.” Mol Metab 29 (November 2019): 99–113. https://doi.org/10.1016/j.molmet.2019.08.019.Full Text Link to Item
-
Kleiner, David E., Elizabeth M. Brunt, Laura A. Wilson, Cynthia Behling, Cynthia Guy, Melissa Contos, Oscar Cummings, et al. “Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.” Jama Netw Open 2, no. 10 (October 2, 2019): e1912565. https://doi.org/10.1001/jamanetworkopen.2019.12565.Full Text Link to Item
-
Gawrieh, Samer, Laura A. Wilson, Oscar W. Cummings, Jeanne M. Clark, Rohit Loomba, Bilal Hameed, Manal F. Abdelmalek, et al. “Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.” Am J Gastroenterol 114, no. 10 (October 2019): 1626–35. https://doi.org/10.14309/ajg.0000000000000388.Full Text Link to Item
-
Lonardo, Amedeo, Fabio Nascimbeni, Stefano Ballestri, DeLisa Fairweather, Sanda Win, Tin A. Than, Manal F. Abdelmalek, and Ayako Suzuki. “Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.” Hepatology 70, no. 4 (October 2019): 1457–69. https://doi.org/10.1002/hep.30626.Full Text Link to Item
-
Rinella, Mary E., Frank Tacke, Arun J. Sanyal, Quentin M. Anstee, and Quentin M. participants of the AASLD/EASL Workshop. “Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.” Hepatology 70, no. 4 (October 2019): 1424–36. https://doi.org/10.1002/hep.30782.Full Text Link to Item
-
Rinella, Mary E., Frank Tacke, Arun J. Sanyal, Quentin M. Anstee, and Quentin M. participants of the AASLD/EASL Workshop. “Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.” J Hepatol 71, no. 4 (October 2019): 823–33. https://doi.org/10.1016/j.jhep.2019.04.019.Full Text Link to Item
-
Loomba, Rohit, Anjali Jain, Anna Mae Diehl, Cynthia D. Guy, Dana Portenier, Ranjan Sudan, Seema Singh, et al. “Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.” Clin Gastroenterol Hepatol 17, no. 9 (August 2019): 1867-1876.e3. https://doi.org/10.1016/j.cgh.2018.11.004.Full Text Link to Item
-
Siddiqui, Mohammad Shadab, Goro Yamada, Raj Vuppalanchi, Mark Van Natta, Rohit Loomba, Cynthia Guy, Danielle Brandman, et al. “Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.” Clin Gastroenterol Hepatol 17, no. 9 (August 2019): 1877-1885.e5. https://doi.org/10.1016/j.cgh.2018.12.031.Full Text Link to Item
-
Chalasani, Naga, Manal F. Abdelmalek, Rohit Loomba, Kris V. Kowdley, Arthur J. McCullough, Srinivasan Dasarathy, Brent A. Neuschwander-Tetri, et al. “Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.” Liver Int 39, no. 5 (May 2019): 924–32. https://doi.org/10.1111/liv.13974.Full Text Link to Item
-
Corey, Kathleen E., Laura A. Wilson, Akif Altinbas, Katherine P. Yates, David E. Kleiner, Raymond T. Chung, Ronald M. Krauss, Naga Chalasani, and Naga NASH Clinical Research Network. “Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.” Aliment Pharmacol Ther 49, no. 9 (May 2019): 1205–13. https://doi.org/10.1111/apt.15216.Full Text Link to Item
-
Rinella, Mary E., James F. Trotter, Manal F. Abdelmalek, Angelo H. Paredes, Margery A. Connelly, Mark J. Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, and Stephen A. Harrison. “Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.” J Hepatol 70, no. 4 (April 2019): 735–44. https://doi.org/10.1016/j.jhep.2018.11.032.Full Text Link to Item
-
Jayakumar, Saumya, Michael S. Middleton, Eric J. Lawitz, Parvez S. Mantry, Stephen H. Caldwell, Hays Arnold, Anna Mae Diehl, et al. “Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.” J Hepatol 70, no. 1 (January 2019): 133–41. https://doi.org/10.1016/j.jhep.2018.09.024.Full Text Link to Item
-
Loomba, Rohit, Arun J. Sanyal, Kris V. Kowdley, Norah Terrault, Naga P. Chalasani, Manal F. Abdelmalek, Arthur J. McCullough, et al. “Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.” Gastroenterology 156, no. 1 (January 2019): 88-95.e5. https://doi.org/10.1053/j.gastro.2018.09.021.Full Text Link to Item
-
Siddiqui, Mohammad S., Raj Vuppalanchi, Mark L. Van Natta, Erin Hallinan, Kris V. Kowdley, Manal Abdelmalek, Brent A. Neuschwander-Tetri, et al. “Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.” Clin Gastroenterol Hepatol 17, no. 1 (January 2019): 156-163.e2. https://doi.org/10.1016/j.cgh.2018.04.043.Full Text Link to Item
-
Younossi, Zobair, Maria Stepanova, Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, et al. “The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.” J Hepatol 69, no. 6 (December 2018): 1365–70. https://doi.org/10.1016/j.jhep.2018.08.013.Full Text Link to Item
-
Glass, Oliver, Ricardo Henao, Keyur Patel, Cynthia D. Guy, Hans J. Gruss, Wing-Kin Syn, Cynthia A. Moylan, et al. “Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.” Hepatol Commun 2, no. 11 (November 2018): 1344–55. https://doi.org/10.1002/hep4.1237.Full Text Link to Item
-
Wildman-Tobriner, Benjamin, Michael M. Middleton, Cynthia A. Moylan, Stephen Rossi, Omar Flores, Zac Anchi Chang, Manal F. Abdelmalek, Claude B. Sirlin, and Mustafa R. Bashir. “Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.” Gastroenterology 155, no. 5 (November 2018): 1428-1435.e2. https://doi.org/10.1053/j.gastro.2018.07.018.Full Text Link to Item
-
Harrison, Stephen A., Manal F. Abdelmalek, Stephen Caldwell, Mitchell L. Shiffman, Anna Mae Diehl, Reem Ghalib, Eric J. Lawitz, et al. “Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.” Gastroenterology 155, no. 4 (October 2018): 1140–53. https://doi.org/10.1053/j.gastro.2018.07.006.Full Text Link to Item
-
Moylan, Cynthia A., and Manal F. Abdelmalek. “Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.” Hepatology 68, no. 4 (October 2018): 1646–48. https://doi.org/10.1002/hep.29879.Full Text Link to Item
-
Yang, Ju Dong, Manal F. Abdelmalek, Cynthia D. Guy, Anna Mae Diehl, and Ayako Suzuki. “Reply.” Clin Gastroenterol Hepatol 16, no. 10 (October 2018): 1684. https://doi.org/10.1016/j.cgh.2017.05.003.Full Text Open Access Copy Link to Item
-
Kleinstein, Sarah E., Matthew Rein, Manal F. Abdelmalek, Cynthia D. Guy, David B. Goldstein, Anna Mae Diehl, and Cynthia A. Moylan. “Whole-Exome Sequencing Study of Extreme Phenotypes of NAFLD.” Hepatology Communications 2, no. 9 (September 5, 2018): 1021–29. https://doi.org/10.1002/hep4.1227.Full Text
-
Younossi, Zobair M., Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander-Tetri, Lawrence Serfaty, et al. “Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.” Hepatology 68, no. 1 (July 2018): 361–71. https://doi.org/10.1002/hep.29724.Full Text Link to Item
-
Younossi, Zobair M., Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander-Tetri, et al. “Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.” Hepatology 68, no. 1 (July 2018): 349–60. https://doi.org/10.1002/hep.29721.Full Text Link to Item
-
Friedman, Scott L., Vlad Ratziu, Stephen A. Harrison, Manal F. Abdelmalek, Guruprasad P. Aithal, Juan Caballeria, Sven Francque, et al. “A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.” Hepatology 67, no. 5 (May 2018): 1754–67. https://doi.org/10.1002/hep.29477.Full Text Link to Item
-
Jensen, Thomas, Manal F. Abdelmalek, Shelby Sullivan, Kristen J. Nadeau, Melanie Green, Carlos Roncal, Takahiko Nakagawa, et al. “Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.” J Hepatol 68, no. 5 (May 2018): 1063–75. https://doi.org/10.1016/j.jhep.2018.01.019.Full Text Link to Item
-
Siddiqui, Mohammad Shadab, Stephen A. Harrison, Manal F. Abdelmalek, Quentin M. Anstee, Pierre Bedossa, Laurent Castera, Lara Dimick-Santos, et al. “Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.” Hepatology 67, no. 5 (May 2018): 2001–12. https://doi.org/10.1002/hep.29607.Full Text Link to Item
-
Harrison, Stephen A., Mary E. Rinella, Manal F. Abdelmalek, James F. Trotter, Angelo H. Paredes, Hays L. Arnold, Marcelo Kugelmas, et al. “NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.” Lancet 391, no. 10126 (March 24, 2018): 1174–85. https://doi.org/10.1016/S0140-6736(18)30474-4.Full Text Link to Item
-
Hameed, B., N. A. Terrault, R. M. Gill, R. Loomba, N. Chalasani, J. H. Hoofnagle, M. L. Van Natta, and M. L. NASH CRN. “Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.” Aliment Pharmacol Ther 47, no. 5 (March 2018): 645–56. https://doi.org/10.1111/apt.14492.Full Text Link to Item
-
Wegermann, Kara, Ricardo Henao, Anna Mae Diehl, Susan K. Murphy, Manal F. Abdelmalek, and Cynthia A. Moylan. “Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.” Plos One 13, no. 9 (2018): e0204308. https://doi.org/10.1371/journal.pone.0204308.Full Text Link to Item
-
Glass, O. K., A. Radia, W. E. Kraus, and M. F. Abdelmalek. “Exercise training as treatment of nonalcoholic fatty liver disease.” Journal of Functional Morphology and Kinesiology 2, no. 4 (December 1, 2017). https://doi.org/10.3390/jfmk2040035.Full Text
-
Newton, Kimberly P., Haruna S. Feldman, Christina D. Chambers, Laura Wilson, Cynthia Behling, Jeanne M. Clark, Jean P. Molleston, et al. “Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.” J Pediatr 187 (August 2017): 141-146.e1. https://doi.org/10.1016/j.jpeds.2017.03.007.Full Text Link to Item
-
Kappus, Matthew, and Manal Abdelmalek. “De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.” Clin Liver Dis 21, no. 2 (May 2017): 321–35. https://doi.org/10.1016/j.cld.2016.12.006.Full Text Link to Item
-
Patel, Yuval A., Ricardo Henao, Cynthia A. Moylan, Cynthia D. Guy, Dawn L. Piercy, Anna Mae Diehl, and Manal F. Abdelmalek. “Reply to Kim et al.” Am J Gastroenterol 112, no. 5 (May 2017): 807–8. https://doi.org/10.1038/ajg.2017.45.Full Text Link to Item
-
Yang, Ju Dong, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Joel E. Lavine, Katherine Yates, Jagpal Klair, et al. “Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.” Clin Gastroenterol Hepatol 15, no. 1 (January 2017): 127-131.e2. https://doi.org/10.1016/j.cgh.2016.07.034.Full Text Link to Item
-
Abdelmalek, Manal F. “NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.” Nat Rev Gastroenterol Hepatol 13, no. 12 (December 2016): 685–86. https://doi.org/10.1038/nrgastro.2016.178.Full Text Link to Item
-
Nelson, J. E., P. Handa, B. Aouizerat, L. Wilson, L. A. Vemulakonda, M. M. Yeh, K. V. Kowdley, and K. V. NASH Clinical Research Network. “Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.” Aliment Pharmacol Ther 44, no. 11–12 (December 2016): 1253–64. https://doi.org/10.1111/apt.13824.Full Text Link to Item
-
Patel, Yuval A., Ricardo Henao, Cynthia A. Moylan, Cynthia D. Guy, Dawn L. Piercy, Anna Mae Diehl, and Manal F. Abdelmalek. “Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.” Am J Gastroenterol 111, no. 11 (November 2016): 1591–98. https://doi.org/10.1038/ajg.2016.406.Full Text Link to Item
-
Klair, Jagpal Singh, Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Katherine Yates, Aynur Unalp-Arida, et al. “A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.” Hepatology 64, no. 1 (July 2016): 85–91. https://doi.org/10.1002/hep.28514.Full Text Link to Item
-
Ratziu, Vlad, Stephen A. Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, et al. “Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.” Gastroenterology 150, no. 5 (May 2016): 1147-1159.e5. https://doi.org/10.1053/j.gastro.2016.01.038.Full Text Link to Item
-
Thrasher, Tyler, and Manal F. Abdelmalek. “Nonalcoholic Fatty Liver Disease.” N C Med J 77, no. 3 (May 2016): 216–19. https://doi.org/10.18043/ncm.77.3.216.Full Text Link to Item
-
Zhu, Ruixin, Susan S. Baker, Cynthia A. Moylan, Manal F. Abdelmalek, Cynthia D. Guy, Fausto Zamboni, Dingfeng Wu, et al. “Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.” J Pathol 238, no. 4 (March 2016): 531–42. https://doi.org/10.1002/path.4650.Full Text Link to Item
-
Abdelmalek, Manal F., and Chris Day. “Sugar sweetened beverages and fatty liver disease: Rising concern and call to action.” J Hepatol 63, no. 2 (August 2015): 306–8. https://doi.org/10.1016/j.jhep.2015.05.021.Full Text Link to Item
-
Deng, Yufeng, Mark L. Palmeri, Ned C. Rouze, Stephen J. Rosenzweig, Manal F. Abdelmalek, and Kathryn R. Nightingale. “Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver.” Ultrasound Med Biol 41, no. 7 (July 2015): 1948–57. https://doi.org/10.1016/j.ultrasmedbio.2015.02.019.Full Text Link to Item
-
Guy, Cynthia, Ayako Suzuki, Manal Abdelmalek, James Burchette, and Anna Mae Diehl. “Reply: To PMID 24849310.” Hepatology (Baltimore, Md.) 61, no. 5 (May 2015): 1770–71. https://doi.org/10.1002/hep.27430.Full Text
-
Neuschwander-Tetri, Brent A., Rohit Loomba, Arun J. Sanyal, Joel E. Lavine, Mark L. Van Natta, Manal F. Abdelmalek, Naga Chalasani, et al. “Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.” Lancet 385, no. 9972 (March 14, 2015): 956–65. https://doi.org/10.1016/S0140-6736(14)61933-4.Full Text Link to Item
-
Guy, Cynthia D., Ayako Suzuki, Manal F. Abdelmalek, James L. Burchette, Anna Mae Diehl, and Anna Mae NASH CRN. “Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.” Hepatology 61, no. 1 (January 2015): 98–107. https://doi.org/10.1002/hep.27235.Full Text Link to Item
-
Nightingale, Kathryn R., Ned C. Rouze, Stephen J. Rosenzweig, Michael H. Wang, Manal F. Abdelmalek, Cynthia D. Guy, and Mark L. Palmeri. “Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging.” Ieee Trans Ultrason Ferroelectr Freq Control 62, no. 1 (January 2015): 165–75. https://doi.org/10.1109/TUFFC.2014.006653.Full Text Link to Item
-
Bohinc, Brittany N., Gregory Michelotti, Guanhua Xie, Herbert Pang, Ayako Suzuki, Cynthia D. Guy, Dawn Piercy, et al. “Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.” Endocrinology 155, no. 11 (November 2014): 4591–4601. https://doi.org/10.1210/en.2014-1302.Full Text Link to Item
-
Sanyal, Arun J., Manal F. Abdelmalek, Ayako Suzuki, Oscar W. Cummings, Mario Chojkier, and Mario EPE-A Study Group. “No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.” Gastroenterology 147, no. 2 (August 2014): 377-84.e1. https://doi.org/10.1053/j.gastro.2014.04.046.Full Text Link to Item
-
Siddique, Asma, James E. Nelson, Bradley Aouizerat, Matthew M. Yeh, Kris V. Kowdley, and Kris V. NASH Clinical Research Network. “Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin.” Clin Gastroenterol Hepatol 12, no. 7 (July 2014): 1170–78. https://doi.org/10.1016/j.cgh.2013.11.017.Full Text Link to Item
-
Kelley, Carly E., Anna Beth Barton, Manal Abdelmalek, Ann Julia Brown, and Tracy Lynn Setji. “Liver Cirrhosis Secondary to Nonalcoholic Fatty Liver Disease in a Patient with Hypopituitarism after Craniopharyngioma Resection.” Endocrine Reviews 35, no. 3 (June 1, 2014).Link to Item
-
Gadd, Victoria L., Richard Skoien, Elizabeth E. Powell, Kevin J. Fagan, Clay Winterford, Leigh Horsfall, Katharine Irvine, and Andrew D. Clouston. “The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease.” Hepatology 59, no. 4 (April 2014): 1393–1405. https://doi.org/10.1002/hep.26937.Full Text
-
Moylan, Cynthia A., Herbert Pang, Andrew Dellinger, Ayako Suzuki, Melanie E. Garrett, Cynthia D. Guy, Susan K. Murphy, et al. “Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.” Hepatology 59, no. 2 (February 2014): 471–82. https://doi.org/10.1002/hep.26661.Full Text Link to Item
-
Sanyal, Arun J., Manal F. Abdelmalek, Ayako Suzuki, Oscar Cummings, and Mario Chojkier. “A Phase 2B Double-Blind Placebo Controlled Study of Two Doses of EPA-E in Patients With Nonalcoholic Steatohepatitis.” Hepatology 58, no. 6 (December 1, 2013): 1385A-1385A.Link to Item
-
Ishimoto, Takuji, Miguel A. Lanaspa, Christopher J. Rivard, Carlos A. Roncal-Jimenez, David J. Orlicky, Christina Cicerchi, Rachel H. McMahan, et al. “High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase.” Hepatology 58, no. 5 (November 2013): 1632–43. https://doi.org/10.1002/hep.26594.Full Text Link to Item
-
Murphy, Susan K., Hyuna Yang, Cynthia A. Moylan, Herbert Pang, Andrew Dellinger, Manal F. Abdelmalek, Melanie E. Garrett, et al. “Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.” Gastroenterology 145, no. 5 (November 2013): 1076–87. https://doi.org/10.1053/j.gastro.2013.07.047.Full Text Link to Item
-
Youssef, Nagy A., Manal F. Abdelmalek, Martin Binks, Cynthia D. Guy, Alessia Omenetti, Alastair D. Smith, Anna Mae E. Diehl, and Ayako Suzuki. “Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease.” Liver Int 33, no. 7 (August 2013): 1062–70. https://doi.org/10.1111/liv.12165.Full Text Link to Item
-
Swiderska-Syn, Marzena, Ayako Suzuki, Cynthia D. Guy, Jeffrey B. Schwimmer, Manal F. Abdelmalek, Joel E. Lavine, and Anna Mae Diehl. “Hedgehog pathway and pediatric nonalcoholic fatty liver disease.” Hepatology (Baltimore, Md.) 57, no. 5 (May 2013): 1814–25. https://doi.org/10.1002/hep.26230.Full Text
-
Corbin, Karen D., Manal F. Abdelmalek, Melanie D. Spencer, Kerry-Ann da Costa, Joseph A. Galanko, Wei Sha, Ayako Suzuki, et al. “Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis.” Faseb J 27, no. 4 (April 2013): 1674–89. https://doi.org/10.1096/fj.12-219097.Full Text Link to Item
-
Garrett, Melanie E., Manal F. Abdelmalek, Allison Ashley-Koch, Michael A. Hauser, Cynthia A. Moylan, Herbert Pang, Anna Mae Diehl, and Hans L. Tillmann. “IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.” J Hepatol 58, no. 2 (February 2013): 402–3. https://doi.org/10.1016/j.jhep.2012.09.035.Full Text Link to Item
-
Nelson, James E., Elizabeth M. Brunt, Kris V. Kowdley, and Kris V. Nonalcoholic Steatohepatitis Clinical Research Network. “Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.” Hepatology 56, no. 5 (November 2012): 1730–40. https://doi.org/10.1002/hep.25856.Full Text Link to Item
-
Bohinc, Brittany, Ayako Suzuki, Cynthia Guy, Herbert Pang, Dawn Piercy, Mark Feinglos, Paul Yen, Anna Mae Diehl, and Manal Abdelmalek. “The Association of Serum Thyroid Hormone Levels and Hepatic Gene Expression of Potential Regulators of Intracellular Thyroid Hormone Concentration with Severity of Nonalcoholic Fatty Liver Disease.” American Journal of Gastroenterology 107 (October 2012): S193–S193. https://doi.org/10.14309/00000434-201210001-00464.Full Text
-
Abdelmalek, Manal F., Mariana Lazo, Alena Horska, Susanne Bonekamp, Edward W. Lipkin, Ashok Balasubramanyam, John P. Bantle, et al. “Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes.” Hepatology 56, no. 3 (September 2012): 952–60. https://doi.org/10.1002/hep.25741.Full Text Link to Item
-
Syn, Wing-Kin, Kolade M. Agboola, Marzena Swiderska, Gregory A. Michelotti, Evaggelia Liaskou, Herbert Pang, Guanhua Xie, et al. “NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.” Gut 61, no. 9 (September 2012): 1323–29. https://doi.org/10.1136/gutjnl-2011-301857.Full Text Link to Item
-
Suzuki, Ayako, Manal F. Abdelmalek, Jeffrey B. Schwimmer, Joel E. Lavine, Ann O. Scheimann, Aynur Unalp-Arida, Katherine P. Yates, et al. “Association between puberty and features of nonalcoholic fatty liver disease.” Clin Gastroenterol Hepatol 10, no. 7 (July 2012): 786–94. https://doi.org/10.1016/j.cgh.2012.01.020.Full Text Link to Item
-
Guy, Cynthia D., Ayako Suzuki, James L. Burchette, Elizabeth M. Brunt, Manal F. Abdelmalek, Diana Cardona, Shannon J. McCall, et al. “Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.” Hum Pathol 43, no. 6 (June 2012): 790–800. https://doi.org/10.1016/j.humpath.2011.07.007.Full Text Link to Item
-
Guy, Cynthia D., Ayako Suzuki, Marzena Zdanowicz, Manal F. Abdelmalek, James Burchette, Aynur Unalp, Anna Mae Diehl, and Anna Mae NASH CRN. “Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.” Hepatology 55, no. 6 (June 2012): 1711–21. https://doi.org/10.1002/hep.25559.Full Text Link to Item
-
Corbin, Karen D., Melanie D. Spencer, Kerry-Ann da Costa, Wei Sha, Manal F. Abdelmalek, Yiping Pan, Ayako Suzuki, et al. “Genotype-based hierarchical clustering reveals a panel of polymorphisms in one carbon metabolism that are associated with obesity.” Faseb Journal 26 (April 1, 2012).Link to Item
-
Palmeri, M. L., M. F. Abdelmalek, and K. R. Nightingale. “Reply to: The use of acoustic radiation force-based shear stiffness in non-alcoholic fatty liver disease.” Journal of Hepatology 56, no. 4 (April 1, 2012): 996. https://doi.org/10.1016/j.jhep.2011.09.007.Full Text
-
Abdelmalek, M. F., A. Humar, F. Stickel, P. Andreone, A. Pascher, E. Barroso, G. W. Neff, et al. “Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 12, no. 3 (March 2012): 694–705. https://doi.org/10.1111/j.1600-6143.2011.03919.x.Full Text
-
Ratziu, Vlad, Muhammad Y. Sheikh, Arun J. Sanyal, Joseph K. Lim, Hari Conjeevaram, Naga Chalasani, Manal Abdelmalek, et al. “A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.” Hepatology 55, no. 2 (February 2012): 419–28. https://doi.org/10.1002/hep.24747.Full Text Link to Item
-
Vos, Miriam B., Ryan Colvin, Patricia Belt, Jean P. Molleston, Karen F. Murray, Philip Rosenthal, Jeffrey B. Schwimmer, et al. “Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.” J Pediatr Gastroenterol Nutr 54, no. 1 (January 2012): 90–96. https://doi.org/10.1097/MPG.0b013e318229da1a.Full Text Link to Item
-
Palmeri, Mark L., Michael H. Wang, Ned C. Rouze, Manal F. Abdelmalek, Cynthia D. Guy, Barry Moser, Anna Mae Diehl, and Kathryn R. Nightingale. “Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.” J Hepatol 55, no. 3 (September 2011): 666–72. https://doi.org/10.1016/j.jhep.2010.12.019.Full Text Link to Item
-
Rangwala, Fatima, Cynthia D. Guy, Jiuyi Lu, Ayako Suzuki, James L. Burchette, Manal F. Abdelmalek, Wei Chen, and Anna Mae Diehl. “Increased production of sonic hedgehog by ballooned hepatocytes.” J Pathol 224, no. 3 (July 2011): 401–10. https://doi.org/10.1002/path.2888.Full Text Link to Item
-
Speliotes, Elizabeth K., Laura M. Yerges-Armstrong, Jun Wu, Ruben Hernaez, Lauren J. Kim, Cameron D. Palmer, Vilmundur Gudnason, et al. “Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.” Plos Genet 7, no. 3 (March 2011): e1001324. https://doi.org/10.1371/journal.pgen.1001324.Full Text Link to Item
-
Syn, Wing-Kin, Steve S. Choi, Evaggelia Liaskou, Gamze F. Karaca, Kolade M. Agboola, Ye Htun Oo, Zhiyong Mi, et al. “Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.” Hepatology 53, no. 1 (January 2011): 106–15. https://doi.org/10.1002/hep.23998.Full Text Link to Item
-
Suzuki, Ayako, Manal F. Abdelmalek, Aynur Unalp-Arida, Katherine Yates, Arun Sanyal, Cynthia Guy, and Anna Mae Diehl. “Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.” Clin Gastroenterol Hepatol 8, no. 12 (December 2010): 1062–69. https://doi.org/10.1016/j.cgh.2010.08.005.Full Text Link to Item
-
Abdelmalek, Manal F., Ayako Suzuki, Cynthia Guy, Aynur Unalp-Arida, Ryan Colvin, Richard J. Johnson, Anna Mae Diehl, and Anna Mae Nonalcoholic Steatohepatitis Clinical Research Network. “Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease.” Hepatology 51, no. 6 (June 2010): 1961–71. https://doi.org/10.1002/hep.23535.Full Text Link to Item
-
Levene, Adam P., Hiromi Kudo, Mark R. Thursz, Quentin M. Anstee, and Robert D. Goldin. “Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?” Hepatology 51, no. 5 (May 2010): 1859. https://doi.org/10.1002/hep.23551.Full Text Link to Item
-
Sánchez-Lozada, Laura G., Wei Mu, Carlos Roncal, Yuri Y. Sautin, Manal Abdelmalek, Sirirat Reungjui, MyPhuong Le, et al. “Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver.” Eur J Nutr 49, no. 1 (February 2010): 1–9. https://doi.org/10.1007/s00394-009-0042-x.Full Text Link to Item
-
Lavine, Joel E., Jeffrey B. Schwimmer, Jean P. Molleston, Ann O. Scheimann, Karen F. Murray, Stephanie H. Abrams, Philip Rosenthal, et al. “Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.” Contemp Clin Trials 31, no. 1 (January 2010): 62–70. https://doi.org/10.1016/j.cct.2009.09.001.Full Text Link to Item
-
Abdelmalek, Manal F., Schuyler O. Sanderson, Paul Angulo, Consuelo Soldevila-Pico, Chen Liu, Joy Peter, Jill Keach, et al. “Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.” Hepatology 50, no. 6 (December 2009): 1818–26. https://doi.org/10.1002/hep.23239.Full Text Link to Item
-
Shah, Amy G., Alison Lydecker, Karen Murray, Brent N. Tetri, Melissa J. Contos, Arun J. Sanyal, and Arun J. Nash Clinical Research Network. “Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.” Clin Gastroenterol Hepatol 7, no. 10 (October 2009): 1104–12. https://doi.org/10.1016/j.cgh.2009.05.033.Full Text Link to Item
-
Syn, Wing-Kin, Youngmi Jung, Alessia Omenetti, Manal Abdelmalek, Cynthia D. Guy, Liu Yang, Jiangbo Wang, et al. “Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease.” Gastroenterology 137, no. 4 (October 2009): 1478-1488.e8. https://doi.org/10.1053/j.gastro.2009.06.051.Full Text Link to Item
-
Brunt, Elizabeth M., David E. Kleiner, Laura A. Wilson, Aynur Unalp, Cynthia E. Behling, Joel E. Lavine, Brent A. Neuschwander-Tetri, and Brent A. NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. “Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.” Hepatology 49, no. 3 (March 2009): 809–20. https://doi.org/10.1002/hep.22724.Full Text Link to Item
-
Suzuki, Ayako, and Manal F. Abdelmalek. “Nonalcoholic fatty liver disease in women.” Womens Health (Lond) 5, no. 2 (March 2009): 191–203. https://doi.org/10.2217/17455057.5.2.191.Full Text Link to Item
-
Ouyang, Xiaosen, Pietro Cirillo, Yuri Sautin, Shannon McCall, James L. Bruchette, Anna Mae Diehl, Richard J. Johnson, and Manal F. Abdelmalek. “Fructose consumption as a risk factor for non-alcoholic fatty liver disease.” J Hepatol 48, no. 6 (June 2008): 993–99. https://doi.org/10.1016/j.jhep.2008.02.011.Full Text Link to Item
-
Chalasani, Naga, Laura Wilson, David E. Kleiner, Oscar W. Cummings, Elizabeth M. Brunt, and Aynur Ünalp. “Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.” Journal of Hepatology 48, no. 5 (May 2008): 829–34. https://doi.org/10.1016/j.jhep.2008.01.016.Full Text
-
Palmeri, M. L., M. H. Wang, K. D. Frinkley, K. R. Nightingale, M. F. Abdelmalek, and A. M. Diehl. “Dependence of in vivo, radiation force derived hepatic shear modulus estimates on imaging approach: Intercostal vs. subcostal.” Proceedings Ieee Ultrasonics Symposium, December 1, 2007, 566–69. https://doi.org/10.1109/ULTSYM.2007.147.Full Text
-
Abdelmalek, Manal F., and Anna Mae Diehl. “Nonalcoholic fatty liver disease as a complication of insulin resistance.” Med Clin North Am 91, no. 6 (November 2007): 1125–ix. https://doi.org/10.1016/j.mcna.2007.06.001.Full Text Link to Item
-
Purohit, Vishnudutt, Manal F. Abdelmalek, Shirish Barve, Norlin J. Benevenga, Charles H. Halsted, Neil Kaplowitz, Kusum K. Kharbanda, et al. “Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium.” Am J Clin Nutr 86, no. 1 (July 2007): 14–24. https://doi.org/10.1093/ajcn/86.1.14.Full Text Link to Item
-
Abdelmalek, Manal F., Chen Liu, and John F. Valentine. “Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.” Am J Gastroenterol 102, no. 6 (June 2007): 1333–34. https://doi.org/10.1111/j.1572-0241.2007.01131.x.Full Text Link to Item
-
Abdelmalek, Manal F., and Anna Mae Diehl. “De novo nonalcoholic fatty liver disease after liver transplantation.” Liver Transpl 13, no. 6 (June 2007): 788–90. https://doi.org/10.1002/lt.21103.Full Text Link to Item
-
Abdelmalek, Manal F., Lane B. Hellner, Marc Zumberg, Victor W. Melgen, and Richard Lottenberg. “Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection.” Dig Dis Sci 52, no. 4 (April 2007): 914–19. https://doi.org/10.1007/s10620-006-9319-6.Full Text Link to Item
-
Galhenage, Sumedha, Keyur Patel, Heathet M. Patton, Terry Walker, William Symonds, Manal F. Abdelmalek, and John G. Mchutchison. “The association of adipokine levels with changes in steatosis following treatment in patients with chronic hepatitis C infection.” Gastroenterology 132, no. 4 (April 1, 2007): A783–A783.Link to Item
-
Galhenage, S., and M. F. Abdelmalek. “The impact of steatosis and alcohol on hepatitis C.” Current Hepatitis Reports 6, no. 2 (January 1, 2007): 39–45. https://doi.org/10.1007/s11901-007-0002-y.Full Text
-
Abdelmalek, M. F., and A. M. Diehl. “Mechanisms underlying nonalcoholic steatohepatitis.” Drug Discovery Today: Disease Mechanisms 3, no. 4 (December 1, 2006): 479–88. https://doi.org/10.1016/j.ddmec.2006.11.001.Full Text
-
Abdelmalek, Manal F., Chen Liu, Jonathan Shuster, David R. Nelson, and Nabih R. Asal. “Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.” Clin Gastroenterol Hepatol 4, no. 9 (September 2006): 1162–69. https://doi.org/10.1016/j.cgh.2006.06.001.Full Text Link to Item
-
Samara, Karim, Chen Liu, Consuelo Soldevila-Pico, David R. Nelson, and Manal F. Abdelmalek. “Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation.” Dig Dis Sci 51, no. 7 (July 2006): 1226–29. https://doi.org/10.1007/s10620-006-8038-3.Full Text Link to Item
-
Machicao, Victor I., Titte R. Srinivas, Alan W. Hemming, Consuelo Soldevila-Pico, Roberto J. Firpi, Alan I. Reed, Giuseppi J. Morelli, David R. Nelson, and Manal F. Abdelmalek. “Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation.” Liver Transpl 12, no. 5 (May 2006): 754–61. https://doi.org/10.1002/lt.20686.Full Text Link to Item
-
Morelli, Giuseppe, Alan Reed, Roberto J. Firpi, Victor Machicao, Manal F. Abdelmalek, Consuelo Soldevilla-Pico, and David R. Nelson. “Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis.” Liver Transpl 12, no. 2 (February 2006): 306–9. https://doi.org/10.1002/lt.20687.Full Text Link to Item
-
Firpi, Roberto J., Haizhen Zhu, Giuseppe Morelli, Manal F. Abdelmalek, Consuelo Soldevila-Pico, Victor I. Machicao, Roniel Cabrera, Alan I. Reed, Chen Liu, and David R. Nelson. “Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.” Liver Transpl 12, no. 1 (January 2006): 51–57. https://doi.org/10.1002/lt.20532.Full Text Link to Item
-
Firpi, Roberto J., Consuelo Soldevila-Pico, Manal F. Abdelmalek, Giuseppe Morelli, Joel Judah, and David R. Nelson. “Short recovery time after percutaneous liver biopsy: should we change our current practices?” Clin Gastroenterol Hepatol 3, no. 9 (September 2005): 926–29. https://doi.org/10.1016/s1542-3565(05)00294-6.Full Text Link to Item
-
Lucey, Michael R., Manal F. Abdelmalek, Rosemarie Gagliardi, Darla Granger, Curtis Holt, Igal Kam, Goran Klintmalm, et al. “A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.” Am J Transplant 5, no. 5 (May 2005): 1111–19. https://doi.org/10.1111/j.1600-6143.2005.00808.x.Full Text Link to Item
-
Reed, A., R. J. Howard, S. Fujita, D. P. Foley, M. R. Langham, J. D. Schold, D. Nelson, et al. “Liver retransplantation: a single-center outcome and financial analysis.” Transplant Proc 37, no. 2 (March 2005): 1161–63. https://doi.org/10.1016/j.transproceed.2004.11.046.Full Text Link to Item
-
Firpi, Roberto J., Manal F. Abdelmalek, Consuelo Soldevila-Pico, Roniel Cabrera, Jonathan J. Shuster, Douglas Theriaque, Alan I. Reed, et al. “One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.” Liver Transpl 10, no. 10 (October 2004): 1240–47. https://doi.org/10.1002/lt.20238.Full Text Link to Item
-
Abdelmalek, Manal F., Roberto J. Firpi, Consuelo Soldevila-Pico, Alan I. Reed, Alan W. Hemming, Chen Liu, James M. Crawford, Gary L. Davis, and David R. Nelson. “Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.” Liver Transpl 10, no. 2 (February 2004): 199–207. https://doi.org/10.1002/lt.20074.Full Text Link to Item
-
Abdelmalek, Manal F., Tousif M. Pasha, Nizar N. Zein, David H. Persing, Russell H. Wiesner, and David D. Douglas. “Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.” Liver Transpl 9, no. 12 (December 2003): 1253–57. https://doi.org/10.1016/j.lts.2003.09.013.Full Text Link to Item
-
Nelson, David R., Zhengkun Tu, Consuelo Soldevila-Pico, Manal Abdelmalek, Haizhen Zhu, Yi Ling Xu, Roniel Cabrera, Chen Liu, and Gary L. Davis. “Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.” Hepatology 38, no. 4 (October 2003): 859–68. https://doi.org/10.1053/jhep.2003.50427.Full Text Link to Item
-
Rosenberg, Eric I., Girish Mishra, and Manal F. Abdelmalek. “Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.” Transplantation 75, no. 5 (March 15, 2003): 730–32. https://doi.org/10.1097/01.TP.0000048491.67462.DA.Full Text Link to Item
-
Firpi, Roberto J., Manal F. Abdelmalek, Consuelo Soldevila-Pico, Alan Reed, Alan Hemming, Richard Howard, William Van Der Werf, et al. “Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.” Liver Transpl 8, no. 11 (November 2002): 1000–1006. https://doi.org/10.1053/jlts.2002.34968.Full Text Link to Item
-
Nelson, D. R., C. Soldevila-Pico, A. Reed, M. F. Abdelmalek, A. W. Hemming, W. J. Van der Werf, R. Howard, and G. L. Davis. “Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.” Liver Transpl 7, no. 12 (December 2001): 1064–70. https://doi.org/10.1053/jlts.2001.29414.Full Text Link to Item
-
Abdelmalek, M. F., P. Angulo, R. A. Jorgensen, P. B. Sylvestre, and K. D. Lindor. “Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study.” American Journal of Gastroenterology 96, no. 9 SUPPL. (October 3, 2001): 2711–17. https://doi.org/10.1016/S0002-9270(01)02691-0.Full Text
-
Abdelmalek, M. F., P. Angulo, R. A. Jorgensen, P. B. Sylvestre, and K. D. Lindor. “Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.” Am J Gastroenterol 96, no. 9 (September 2001): 2711–17. https://doi.org/10.1111/j.1572-0241.2001.04129.x.Full Text Link to Item
-
Maiwald, M., A. von Herbay, D. H. Persing, P. P. Mitchell, M. F. Abdelmalek, J. N. Thorvilson, D. N. Fredricks, and D. A. Relman. “Tropheryma whippelii DNA is rare in the intestinal mucosa of patients without other evidence of Whipple disease.” Ann Intern Med 134, no. 2 (January 16, 2001): 115–19. https://doi.org/10.7326/0003-4819-134-2-200101160-00011.Full Text Link to Item
-
O’Duffy, J. D., W. L. Griffing, C. Y. Li, M. F. Abdelmalek, and D. H. Persing. “Whipple's arthritis: direct detection of Tropheryma whippelii in synovial fluid and tissue.” Arthritis Rheum 42, no. 4 (April 1999): 812–17. https://doi.org/10.1002/1529-0131(199904)42:4<812::AID-ANR27>3.0.CO;2-S.Full Text Link to Item
-
Abdelmalek, M. F., M. E. Harrison, J. B. Gross, J. J. Poterucha, A. A. Gossard, J. R. Spivey, J. Rakela, and K. D. Lindor. “Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.” J Clin Gastroenterol 26, no. 2 (March 1998): 130–34. https://doi.org/10.1097/00004836-199803000-00009.Full Text Link to Item
-
Abdelmalek, M. F., B. A. Pockaj, and J. A. Leighton. “Rectal bleeding from a mucous fistula secondary to a Dieulafoy's lesion.” J Clin Gastroenterol 24, no. 4 (June 1997): 259–61. https://doi.org/10.1097/00004836-199706000-00017.Full Text Link to Item
-
Abdelmalek, M. F., and D. D. Douglas. “Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema.” Dig Dis Sci 42, no. 4 (April 1997): 847–50. https://doi.org/10.1023/a:1018884702345.Full Text Link to Item
-
Abdelmalek, M. F., and D. D. Douglas. “Alendronate-induced ulcerative esophagitis.” The American Journal of Gastroenterology 91, no. 6 (June 1996): 1282–83.
-
Abdelmalek, M. F., and P. C. Spittell. “79-year-old woman with blue toes.” Mayo Clin Proc 70, no. 3 (March 1995): 292–95. https://doi.org/10.4065/70.3.292.Full Text Link to Item
-
Abdelmalek, M., J. Ludwig, and K. D. Lindor. “Two cases from the spectrum of nonalcoholic steatohepatitis.” J Clin Gastroenterol 20, no. 2 (March 1995): 127–30. https://doi.org/10.1097/00004836-199503000-00011.Full Text Link to Item
-
Wegermann, Kara, Catherine Howe, Ricardo Henao, Ying Wang, Cynthia D. Guy, Manal F. Abdelmalek, Anna Mae Diehl, and Cynthia A. Moylan. “Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver‐Related Events in Nonalcoholic Fatty Liver Disease.” Hepatology Communications, n.d. https://doi.org/10.1002/hep4.1665.Full Text
-
Wegermann, Kara, Melanie E. Garrett, Jiayin Zheng, Andrea Coviello, Cynthia A. Moylan, Manal F. Abdelmalek, Shein‐Chung Chow, et al. “Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD.” Hepatology Communications, n.d. https://doi.org/10.1002/hep4.1668.Full Text
-
-
Conference Papers
-
Abdelmalek, Manal F., Lei Ling, Marno C. Ryan, Stuart K. Roberts, James F. Trotter, Angelo Paredes, Guy Neff, et al. “ALDAFERMIN (NGM282) IMPROVES APRI, FIB-4 AND OTHER NON-INVASIVE MEASURES IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS.” In Hepatology, 72:890A-891A, 2020.Link to Item
-
Bosch, Jaime, Stephen A. Harrison, Manal F. Abdelmalek, Mitchell L. Shiffman, Don C. Rockey, Dinkar Juyal, Zahil Shanis, et al. “A MACHINE LEARNING MODEL BASED ON LIVER HISTOLOGY PREDICTS THE HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH).” In Hepatology, 72:887A-888A, 2020.Link to Item
-
Clark, Danielle L., Aaron R. Pankiewicz, Brian T. Ketterman, Courtney M. Richman, Ying Wang, Manal F. Abdelmalek, and Alisha Mavis. “FAILURE OF CLINICAL NAFLD SCORES TO RELIABLY PREDICT FIBROSIS SEVERITY IN A DIVERSE PEDIATRIC POPULATION.” In Hepatology, 72:877A-878A, 2020.Link to Item
-
Francque, Sven M., Pierre Bedossa, Vlad Ratziu, Quentin M. Anstee, Elisabetta Bugianesi, Arun J. Sanyal, Rohit Loomba, et al. “THE PANPPAR AGONIST LANIFIBRANOR INDUCES BOTH RESOLUTION OF NASH AND REGRESSION OF FIBROSIS AFTER 24 WEEKS OF TREATMENT IN NON-CIRRHOTIC NASH: RESULTS OF THE NATIVE PHASE 2b TRIAL.” In Hepatology, 72:9A-11A, 2020.Link to Item
-
Francque, Sven M., Pierre Bedossa, Vlad Ratziu, Quentin M. Anstee, Elisabetta Bugianesi, Arun J. Sanyal, Rohit Loomba, et al. “SELECTION BASED ON SAF ACTIVITY SCORE, NOT NASH CRN NAFLD ACTIVITY SCORE, LEADS TO SELECTION OF A PATIENT COHORT WITH MORE SEVERE NASH WITH MORE ADVANCED FIBROSIS: EXPERIENCE FROM THE NATIVE PHASE 2b STUDY OF THE PANPPAR AGONIST LANIFIBRANOR.” In Hepatology, 72:1033–35, 2020.Link to Item
-
Kowdley, Kris V., William Alazawi, Nicolas Lanthier, Alexandru Iacob, Richard Torstenson, Star Seyedkazemi, Gerardo Rodriguez-Araujo, Manal F. Abdelmalek, and Arun J. Sanyal. “IMPACT ON INFLAMMATORY BIOMARKERS, LIPIDS, AND CARDIOVASCULAR SAFETY OF CENICRIVIROC WITH OR WITHOUT STATINS IN SUBJECTS WITH NASH AND SIGNIFICANT LIVER FIBROSIS: CENTAUR STUDY.” In Hepatology, 72:1050–51, 2020.Link to Item
-
Moylan, Cynthia A., Dereje Jima, Alisha Mavis, Anna Mae Diehl, Stephanie Buie, Mustafa Bashir, Jeongeun Hyun, et al. “NONALCOHOLIC FATTY LIVER AND ITS RISK FACTORS ASSOCIATE WITH DIFFERENTIAL DNA METHYLATION IN THE PERIPHERAL BLOOD OF PRE-TEENAGE CHILDREN.” In Hepatology, 72:931A-931A, 2020.Link to Item
-
Pankiewicz, Aaron R., Danielle L. Clark, Brian T. Ketterman, Courtney M. Richman, Ying Wang, Manal F. Abdelmalek, and Alisha Mavis. “BEDSIDE LIVER ULTRASOUNDS PERFORMED BY RESIDENT PHYSICIANS YIELD QUALITY IMAGES FOR EVALUATING ECHOGENICITY.” In Hepatology, 72:873A-874A, 2020.Link to Item
-
Pankiewicz, Aaron R., Danielle L. Clark, Brian T. Ketterman, Courtney M. Richman, Ying Wang, Manal F. Abdelmalek, and Alisha Mavis. “EVALUATION OF LIVER ULTRASOUND AS A SCREENING MODALITY FOR PEDIATRIC NAFLD AND FACTORS ASSOCIATED WITH STEATOSIS ON ULTRASOUND.” In Hepatology, 72:877A-877A, 2020.Link to Item
-
Sanyal, Arun J., Quentin M. Anstee, Michael H. Trauner, Eric J. Lawitz, Manal F. Abdelmalek, Dora Ding, Ling Han, et al. “CIRRHOSIS REGRESSION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH).” In Hepatology, 72:67A-68A, 2020.Link to Item
-
Sarkar, Monika, Ayako Suzuki, Manal F. Abdelmalek, Nathan M. Bass, Laura Wilson, Katherine Yates, Marcelle Cedars, Ryan Gill, and Norah Terrault. “TESTOSTERONE IS A KEY RISK FACTOR FOR NONALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS IN YOUNG PRE-MENOPAUSAL WOMEN WITH FATTY LIVER.” In Hepatology, 72:996–97, 2020.Link to Item
-
Suzuki, Ayako, Ying Wang, Andrea D. Coviello, Data D. Portenier, Cynthia A. Moylan, Dawn L. Piercy, Cynthia D. Guy, Anna Mae Diehl, and Manal F. Abdelmalek. “HISTORY OF BREASTFEEDING IS ASSOCIATED WITH A DECREASED RISK OF HEPATIC FIBROSIS AMONG YOUNG WOMEN WITH NAFLD.” In Hepatology, 72:65A-65A, 2020.Link to Item
-
Woreta, Tinsay A., Mark Van Natta, Mariana Lazo, Raj Vuppalanchi, Mohammad B. Siddiqui, Naga P. Chalasani, Samer Gawrieh, et al. “SERUM AMINOTRANSFERASE LEVELS ALONE ARE AS ACCURATE AS TRANSIENT ELASTOGRAPHY AND MORE ACCURATE THAN OTHER ALGORITHMS IN IDENTIFYING AT-RISK NASH.” In Hepatology, 72:942–43, 2020.Link to Item
-
Ratziu, Vlad, Arun Sanyal, Stephen A. Harrison, Vincent Wai-Sun Wong, Sven Francque, Zachary Goodman, Guruprasad P. Aithal, et al. “Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.” In Hepatology, 72:892–905, 2020. https://doi.org/10.1002/hep.31108.Full Text Link to Item
-
ALEXOPOULOS, A. N. A. S. T. A. S. I. A. -. S. T. E. F. A. N. I. A., M. A. T. T. H. E. W. CROWLEY, Y. I. N. G. WANG, CYNTHIA D. GUY, R. I. C. A. R. D. O. HENAO, KERI A. SEYMOUR, R. A. N. J. A. N. SUDAN, et al. “1839-P: Glycemic Control Impacts Severity of Hepatic Fibrosis in NAFLD/NASH.” In Diabetes, 69:1839-P. American Diabetes Association, 2020. https://doi.org/10.2337/db20-1839-p.Full Text
-
COVIELLO, ANDREA D., G. E. R. A. R. D. O. RODRIGUEZ, EDUARDO B. MARTINS, N. A. I. M. ALKHOURI, and MANAL F. ABDELMALEK. “1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study.” In Diabetes, 69:1848-P. American Diabetes Association, 2020. https://doi.org/10.2337/db20-1848-p.Full Text
-
Francque, Sven M., Alexander Hodge, Jerome Boursier, Sam Moussa, Ziad H. Younes, Grace S. Park, Gerardo Rodriguez, et al. “LONG-TERM SAFETY PROFILE OF CENICRIVIROC IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS: ROLLOVER STUDY.” In Gastroenterology, 158:S1446–47, 2020.Link to Item
-
Rinella, Mary E., Michael Allison, Philippe Mathurin, Eric Lawitz, Quentin M. Anstee, Ingolf Schiefke, Salvatore Petta, et al. “OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY.” In Gastroenterology, 158:S1406–7, 2020.Link to Item
-
Satapathy, Sanjaya K., Yu Jiang, Uchenna Agbim, Cen Wu, David E. Bernstein, Lewis W. Teperman, Satish K. Kedia, et al. “Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.” In Liver Transpl, 26:68–79, 2020. https://doi.org/10.1002/lt.25672.Full Text Link to Item
-
Du, Kuo, Seh Hoon Oh, Tianai Sun, Wen-Hsuan Yang, Jen-Tsan Ashley Chi, and Anna Mae Diehl. “Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells and protects against liver fibrosis,” 2019. https://doi.org/10.1101/2019.12.23.886259.Full Text
-
Anstee, Quentin M., Brent A. Neuschwander-Tetri, Vincent Wai-Sun Wong, Manal F. Abdelmalek, Zobair Younossi, Naim Alkhouri, Jiacheng Yuan, et al. “2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design.” In American Journal of Gastroenterology, 114:S1601–2. Ovid Technologies (Wolters Kluwer Health), 2019. https://doi.org/10.14309/01.ajg.0000601300.34038.4b.Full Text
-
Glass, Oliver, Ying Wang, Daniel Liu, Cynthia D. Guy, Anna Mae Diehl, and Manal F. Abdelmalek. “EXERCISE BEHAVIOR IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE.” In Hepatology, 70:748A-748A. WILEY, 2019.Link to Item
-
Harrison, Stephen A., Eric J. Lawitz, Vincent Wai-Sun Wong, Quentin M. Anstee, Michael H. Trauner, Manuel Romero-Gomez, Bal Bhandari, et al. “CURRENTLY AVAILABLE NONINVASIVE TESTS ACCURATELY STAGE FIBROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH).” In Hepatology, 70:1349A-1350A. WILEY, 2019.Link to Item
-
Moylan, Cynthia A., Kuo Du, Jeongeun Hyun, Kara Wegermann, Manal F. Abdelmalek, Anna Mae Diehl, and Cynthia D. Guy. “EXPRESSION OF BRANCHED CHAIN AMINO ACID TRANSAMINASE 1 (BCAT1) IS INCREASED IN NAFLD FIBROSIS AND CIRRHOSIS AND HEPATOCELLULAR CARCINOMA.” In Hepatology, 70:1335A-1336A. WILEY, 2019.Link to Item
-
Wegermann, Kara, Catherine Howe, Ricardo Henao, Ying Wang, Anna Mae Diehl, Manal F. Abdelmalek, and Cynthia A. Moylan. “PRIMARY BILE ACID AND BRANCHED CHAIN AMINO ACID METABOLITES ASSOCIATE WITH DIASTOLIC HEART FAILURE IN NON-ALCOHOLIC FATTY LIVER DISEASE.” In Hepatology, 70:1039A-1039A. WILEY, 2019.Link to Item
-
ABDELMALEK, MANAL F., RALPH W. CHARLTON, EDUARDO B. MARTINS, B. I. L. L. TAN, ANDREA D. COVIELLO, and N. A. I. M. ALKHOURI. “1148-P: Cenicriviroc Safety in over 1,200 Subjects.” In Diabetes, 68:1148-P. American Diabetes Association, 2019. https://doi.org/10.2337/db19-1148-p.Full Text
-
ALKHOURI, N. A. I. M., RALPH W. CHARLTON, EDUARDO B. MARTINS, H. E. N. R. I. K. LANDGREN, ANDREA D. COVIELLO, and MANAL F. ABDELMALEK. “136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis.” In Diabetes, 68:136-OR. American Diabetes Association, 2019. https://doi.org/10.2337/db19-136-or.Full Text
-
COVIELLO, ANDREA D., RALPH W. CHARLTON, EDUARDO B. MARTINS, J. I. A. C. H. E. N. G. YUAN, N. A. I. M. ALKHOURI, and MANAL F. ABDELMALEK. “1164-P: Effects of Cenicriviroc in Adults with NASH on Inflammatory Cytokines and Metabolic Parameters.” In Diabetes, 68:1164-P. American Diabetes Association, 2019. https://doi.org/10.2337/db19-1164-p.Full Text
-
Moylan, Cynthia A., Carole Grenier, Jeongeun Hyun, Kuo Du, Ricardo Henao, Manal F. Abdelmalek, Susan K. Murphy, and Anna Mae Diehl. “DYSREGULATED DNA METHYLATION OF FGFR2, CASP1, AND BCAT1 ASSOCIATES WITH NONALCOHOLIC FATTY LIVER DISEASE SEVERITY AND CAN BE IDENTIFIED IN PERIPHERAL BLOOD.” In Gastroenterology, 156:S1360–61. W B SAUNDERS CO-ELSEVIER INC, 2019.Link to Item
-
Wegermann, Kara, Catherine Howe, Ricardo Henao, Ying Wang, Anna Mae Diehl, Manal F. Abdelmalek, and Cynthia A. Moylan. “BRANCHED CHAIN AMINO ACID AND BILE ACID METABOLITES ASSOCIATE WITH FUTURE CLINICAL DECOMPENSATION IN NONALCOHOLIC FATTY LIVER DISEASE.” In Gastroenterology, 156:S1223–S1223. W B SAUNDERS CO-ELSEVIER INC, 2019.Link to Item
-
Garcia-Tsao, Guadalupe, Jaime Bosch, Zeid Kayali, Stephen Harrison, Manal Abdelmalek, Eric Lawitz, Sanjaya Satapathy, et al. “LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension.” In Journal of Hepatology, 70:e127–e127. Elsevier BV, 2019. https://doi.org/10.1016/s0618-8278(19)30225-7.Full Text
-
Schild, Michael, Manal Abdelmalek, Anna Mae Diehl, and Cynthia Guy. “Sonic hedgehog immunohistochemistry is a tissue biomarker of ballooned hepatocytes.” In Journal of Hepatology, 70:E782–83. ELSEVIER, 2019.Link to Item
-
Paredes, Angelo H., James F. Trotter, Mustafa R. Bashir, Guy W. Neff, Manal F. Abdelmalek, Grisell Ortiz-Lasanta, Mark Jaros, et al. “NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study.” In Hepatology, 68:1460A-1461A. WILEY, 2018.Link to Item
-
Abdelmalek, Manal F., Bradley L. Freilich, Stephen A. Harrison, Elizabeth E. Powell, Mary E McCarthy Rinella, Neta Tobis, Dan Peres, Jerry Kanellos, Gadi Lalazar, and Arun J. Sanyal. “Imm-124E Improves Metabolic Endotoxemia and Markers of Liver Injury in Nonalcoholic Steatohepatitis.” In Hepatology, 68:68A-69A. WILEY, 2018.Link to Item
-
Abdelmalek, Manal F., Nicolas Lanthier, Mario Chojkier, Johannes Kluwe, Andrew J. Fowell, Jiacheng Yuan, Jean Paul Nicandro, et al. “Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis.” In Hepatology, 68:1287A-1287A. WILEY, 2018.Link to Item
-
Chalasani, Naga P., Eric J. Lawitz, Manal F. Abdelmalek, Mary E McCarthy Rinella, Stephen A. Harrison, Arun J. Sanyal, Mazen Noureddin, et al. “The Noninvasive Point of Care MBT Accurately Predicts Decompensation Events Better Than MELD in Compensated (MELD < 15) Nash Cirrhotics.” In Hepatology, 68:769A-770A. WILEY, 2018.Link to Item
-
Chaudhry, Mohammad, Cynthia A. Moylan, Michael S. Middleton, Alfredo Farjat, Kingshuk Roy Chaudhury, Cynthia D. Guy, Manal F. Abdelmalek, Rohit Loomba, Claude B. Sirlin, and Mustafa Bashir. “Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials.” In Hepatology, 68:68A-68A. WILEY, 2018.Link to Item
-
Halegoua-De Marzio, Dina, Paul J. Thuluvath, Manal F. Abdelmalek, Courtney Van Biene, Reshma Shringarpure, and Leigh MacConell. “Obeticholic Acid Was Safe and Well Tolerated in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis: A Secondary Analysis of the Control Study.” In Hepatology, 68:45A-45A. WILEY, 2018.Link to Item
-
Johnson, Alyson M., Naomi Chou, Rachel Feder, Joshua P. Lee, Manal Abdelmalek, and Rebecca A. Burbridge. “Prevalence of Risk Factors for and Presence of Non-Alcoholic Fatty Liver Disease in Patients Receiving Upper Endoscopic Ultrasound.” In American Journal of Gastroenterology, 113:S558–S558. NATURE PUBLISHING GROUP, 2018.Link to Item
-
Moylan, Cynthia A., Patricia A. Sorrow, Alisha Mavis, Mustafa Bashir, Dereje Jima, Rachel Maguire, Erol Bozdogan, et al. “Obesity and Nonalcoholic Fatty Liver Disease in Childhood Associate with Altered DNA Methylation in Early Life.” In Hepatology, 68:949A-950A. WILEY, 2018.Link to Item
-
Neuschwander-Tetri, Brent A., Kris V. Kowdley, Arun J. Sanyal, Manal F. Abdelmalek, Norah Terrault, Arthur J. McCullough, Peter Wang, et al. “Efficacy and Safety of Obeticholic Acid in Patients with Non-Alcoholic Steatohepatitis and Significant Fibrosis Using Endpoint Definitions and Populations Accepted for Registrational Studies.” In Hepatology, 68:952A-952A. WILEY, 2018.Link to Item
-
Bae, Andrew, Ricardo Henao, Ayako Suzuki, Cynthia A. Moylan, Cynthia D. Guy, Anna Mae Diehl, and Manal F. Abdelmalek. “STATIN USE AND LIVER INJURY IN NONALCOHOLIC FATTY LIVER DISEASE: RESULTS OF A PAIRED CLINICAL AND GENE EXPRESSION PROFILE ANALYSIS.” In Gastroenterology, 154:S1085–86. W B SAUNDERS CO-ELSEVIER INC, 2018.Link to Item
-
DEPAOLI, A. L. E. X., STEPHEN J. ROSSI, L. E. I. LING, STEPHEN A. HARRISON, MANAL F. ABDELMALEK, MARK R. JAROS, and R. A. N. S. I. SOMARATNE. “NGM282 Significantly Reduces Hepatic Steatosis Independent of Type 2 Diabetes (T2D) Status or Statin Usage—Results from a Phase 2 Trial in Patients with Nonalcoholic Steatohepatitis (NASH).” In Diabetes, 67:1-LB. American Diabetes Association, 2018. https://doi.org/10.2337/db18-1-lb.Full Text
-
Du, Kuo, Richard Premont, Jeongeun Hyun, Mariana V. Machado, Cynthia A. Moylan, Manal F. Abdelmalek, Cynthia D. Guy, and Anna Mae Diehl. “PATHPHYSIOLOGICAL ROLE OF GLUTAMINOLYSIS IN HUMAN NAFLD PROGRESSION.” In Gastroenterology, 154:S950–51. W B SAUNDERS CO-ELSEVIER INC, 2018.Link to Item
-
Ridder, Gustaaf de, Ayako Suzuki, Liyan Xu, Diana Cardona, Jeff Groth, Rupa Ray, Manal F. Abdelmalek, Salvatore V. Pizzo, and Cynthia Guy. “GRP78 Immunohistochemistry Outperforms HSP70 for the Diagnosis of Cirrhotic- and Noncirrhotic-HCC.” In Modern Pathology, 31:632–632. NATURE PUBLISHING GROUP, 2018.Link to Item
-
Ridder, Gustaaf de, Ayako Suzuki, Liyan Xu, Diana Cardona, Jeff Groth, Rupa Ray, Manal F. Abdelmalek, Salvatore V. Pizzo, and Cynthia Guy. “GRP78 Immunohistochemistry Outperforms HSP70 for the Diagnosis of Cirrhotic- and Noncirrhotic-HCC.” In Laboratory Investigation, 98:632–632. NATURE PUBLISHING GROUP, 2018.Link to Item
-
Schild, Michael, Liyan Xu, Ayako Suzuki, Diana Cardona, Lani Clinton, Shannon McCall, Avani Pendse, et al. “Sonic Hedgehog Immunohistochemistry Improves Inter-observer Agreement for Ballooning and the Diagnosis of Nonalcoholic Steatohepatitis (NASH) among Less Experienced Liver Pathologists.” In Modern Pathology, 31:648–49. NATURE PUBLISHING GROUP, 2018.Link to Item
-
Schild, Michael, Liyan Xu, Ayako Suzuki, Diana Cardona, Lani Clinton, Shannon McCall, Avani Pendse, et al. “Sonic Hedgehog Immunohistochemistry Improves Inter-observer Agreement for Ballooning and the Diagnosis of Nonalcoholic Steatohepatitis (NASH) among Less Experienced Liver Pathologists.” In Laboratory Investigation, 98:648–49. NATURE PUBLISHING GROUP, 2018.Link to Item
-
Abdelmalek, Manal F., Anna Mae Diehl, Cynthia D. Guy, Dana Portenier, Ranjan Sudan, Xiaojun Li, Larry Mimms, and Anjali Jain. “Serum-Based Biomarker Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis.” In Hepatology, 66:55A-56A. WILEY, 2017.Link to Item
-
Abdelmalek, Manal F., Edgar D. Charles, Brent A. Neuschwander-Tetri, Dina Halegoua-DeMarzio, Arun J. Sanyal, Robert W. Herring, Eric Lawitz, et al. “Baseline Serum Pro-C3 Predicts Response to BMS-986036 (peg-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH).” In Hepatology, 66:1114A-1115A. WILEY, 2017.Link to Item
-
Abdelmalek, Manal F., Melanie Thompson, Joseph C. Gathe, Eric Lefebvre, Star Seyedkazemi, Netanya Sandler Utay, and Sven Francque. “Favorable safety and tolerability of the dual CCR2/5 antagonist cenicriviroc in over 1000 subjects treated to date.” In Hepatology, 66:1177A-1177A. WILEY, 2017.Link to Item
-
Abdelmalek, Manal F., Ricardo Henao, Ying Wang, Cynthia D. Guy, Mustafa R. Bashir, Richard Johnson, Anna Mae Diehl, and Brian Soher. “Fructose-Related Hepatic ATP Depletion Induces Hyperuricemia in Healthy Volunteers and Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.” In Hepatology, 66:1104A-1105A. WILEY, 2017.Link to Item
-
Bosch, Jaime, Manal F. Abdelmalek, Mitchell L. Shiffman, Anna Mae Diehl, Stephen H. Caldwell, Don C. Rockey, Reem Ghalib, et al. “Variability in measurement of hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to NASH: Results from a randomized, controlled trial.” In Hepatology, 66:252A-252A. WILEY, 2017.Link to Item
-
Bosch, Jaime, Stephen A. Harrison, Manal F. Abdelmalek, Mitchell L. Shiffman, Anna Mae Diehl, Stephen H. Caldwell, Don C. Rockey, et al. “Hepatic venous pressure gradient (HVPG) predicts clinical disease progression in patients with compensated cirrhosis due to NASH.” In Hepatology, 66:244A-245A. WILEY, 2017.Link to Item
-
Goodman, Zachary D., Lakshmi Alaparthi, Fanny Monge, Keyur Patel, Rohit Loomba, Stephen H. Caldwell, Eric Lawitz, et al. “Prospective validation of hepatic collagen content for the prediction of clinical disease progression.” In Hepatology, 66:1111A-1112A. WILEY, 2017.Link to Item
-
Guy, Cynthia D., Ayako Suzuki, Marzena Swiderska-Syn, Manal F. Abdelmalek, and Anna Mae Diehl. “Hepatocellular injury and senescence in NASH are linked to Hedgehog and Hippo pathway activity and accumulation of hepatic progenitor cells.” In Hepatology, 66:1153A-1154A. WILEY, 2017.Link to Item
-
Harrison, Stephen A., Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, Reem Ghalib, Eric Lawitz, et al. “Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis.” In Hepatology, 66:1120A-1121A. WILEY, 2017.Link to Item
-
Li, Xiaoyi, Cynthia A. Moylan, Susan S. Baker, Wensheng Liu, Robert D. Baker, Susan K. Murphy, Manal F. Abdelmalek, Ruixin Zhu, Anna Mae Diehl, and Lixin Zhu. “Altered liver methylome and transcriptome provide evidence for epigenetic contribution to NAFLD pathogenesis.” In Hepatology, 66:1071A-1072A. WILEY, 2017.Link to Item
-
Loomba, Rohit, Eric Lawitz, Reem Ghalib, Magdy Elkhashab, Stephen H. Caldwell, Manal F. Abdelmalek, Kris V. Kowdley, et al. “Reductions in liver stiffness by magnetic resonance elastography (MRE) predict fibrosis improvement in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH).” In Hepatology, 66:1109A-1110A. WILEY, 2017.Link to Item
-
Loomba, Rohit, Manal F. Abdelmalek, James F. Trotter, Angelo H. Paredes, Mark Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, Mary E. Rinella, and Stephen A. Harrison. “NGM282 Significantly Reduces Hepatic Steatosis Independent of Baseline Patient Characteristics and Highly Correlates with Markers of FGFR4 Target Engagement: Results from a Phase 2 Trial in Biopsy-Confirmed NASH Patients.” In Hepatology, 66:1152A-1152A. WILEY, 2017.Link to Item
-
Moylan, Cynthia A., Alisha M. Mavis, Mustafa R. Bashir, David Malik, Erol Bozdogan, Stephanie Buie, Cathrine Hoyo, Anna Mae Diehl, Susan K. Murphy, and Manal F. Abdelmalek. “Visceral and subcutaneous adipose tissue measurements associate with increased metabolic risk for NAFLD in pre-pubertal obese children.” In Hepatology, 66:665A-665A. WILEY, 2017.Link to Item
-
Rinella, Mary E., James F. Trotter, Guy Neff, Grisell Ortiz-Lasanta, Manal F. Abdelmalek, Marcelo Kugelmas, Angelo H. Paredes, et al. “NGM282 Induces Low Density Lipoprotein Cholesterol (LDLc) Changes, Consistent with Potent FGFR4 Signaling, which are Rapidly Mitigated with Statin Therapy in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH).” In Hepatology, 66:1132A-1133A. WILEY, 2017.Link to Item
-
Sanyal, Arun J., Edgar D. Charles, Brent A. Neuschwander-Tetri, Rohit Loomba, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, et al. “BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: A phase 2 study.” In Hepatology, 66:104A-105A. WILEY, 2017.Link to Item
-
Vuppalanchi, Raj, Eric Lawitz, Manal F. Abdelmalek, Mary E. Rinella, Stephen A. Harrison, Michael J. Ryan, Peter G. Traber, Guadalupe Garcia-Tsao, and Naga P. Chalasani. “Liver Stiffness Measured By Vibration Controlled Transient Elastography Is An Excellent Surrogate for Identifying Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis.” In Hepatology, 66:245A-245A. WILEY, 2017.Link to Item
-
Wegermann, Kara, Cynthia A. Moylan, Jiayin Zheng, Manal F. Abdelmalek, Shein-Chung Chow, Cynthia D. Guy, Anna Mae Diehl, and Ayako Suzuki. “Gender and menopause significantly modify effects of metabolism-related SNPs on fibrosis stage in adult patients with nonalcoholic fatty liver disease (NAFLD).” In Hepatology, 66:55A-55A. WILEY, 2017.Link to Item
-
Younossi, Zobair M., Maria Stepanova, Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Bryan J. McColgan, Robert P. Myers, et al. “Predictors of Fibrosis Progression and Regression by Histology and Morphometrically Quantified Collagen in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis.” In Hepatology, 66:1171A-1171A. WILEY, 2017.Link to Item
-
Younossi, Zobair M., Maria Stepanova, Stephen A. Harrison, Arun J. Sanyal, Vlad Ratziu, Bryan J. McColgan, Robert P. Myers, et al. “Subjects with Non-alcoholic Fatty Liver Disease and Severe Fibrosis Face a Significant Number of Adverse Events: Cryptogenic Cirrhosis and Severe Steatofibrosis.” In Hepatology, 66:1154A-1155A. WILEY, 2017.Link to Item
-
Moylan, Cynthia A., Ricardo Henao Giraldo, Susan K. Murphy, Anna Mae Diehl, and Manal F. Abdelmalek. “Differential DNA Methylation in Whole Blood Reflects that in Liver and Distinguishes Patients with Advanced NAFLD Fibrosis from Those with Normal Histology: A Potential Non-Invasive Tool.” In Gastroenterology, 152:S1069–70. Elsevier BV, 2017. https://doi.org/10.1016/s0016-5085(17)33611-9.Full Text
-
Sanyal, Arun, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen H. Caldwell, Mitchell L. Shiffman, et al. “Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis.” In Gastroenterology, 152:S1055–S1055. Elsevier BV, 2017. https://doi.org/10.1016/s0016-5085(17)33563-1.Full Text
-
Shaar, Mohanad, Ayako Suzuki, Craig Poster, Gustaaf de Ridder, Xuefeng Zhang, Mary Kate Cronin, Shannon McCall, et al. “Serum Amyloid A (SAA) and C-Reactive Protein (CRP) Are Commonly Positive in Hepatocellular Carcinoma and Expression Levels Stratify According to Etiology and the Absence of Cirrhosis.” In Laboratory Investigation, 97:424A-425A. NATURE PUBLISHING GROUP, 2017.Link to Item
-
Shaar, Mohanad, Ayako Suzuki, Craig Poster, Gustaaf de Ridder, Xuefeng Zhang, Mary Kate Cronin, Shannon McCall, et al. “Serum Amyloid A (SAA) and C-Reactive Protein (CRP) Are Commonly Positive in Hepatocellular Carcinoma and Expression Levels Stratify According to Etiology and the Absence of Cirrhosis.” In Modern Pathology, 30:424A-425A. NATURE PUBLISHING GROUP, 2017.Link to Item
-
Bosch, J., S. Harrison, V. Ratziu, M. Shiffman, A. Diehl, S. Caldwell, D. Rockey, et al. “Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis.” In Journal of Hepatology, 66:S159–60. Elsevier BV, 2017. https://doi.org/10.1016/s0168-8278(17)30593-7.Full Text
-
Harrison, S. A., M. F. Abdelmalek, J. F. Trotter, A. H. Paredes, H. L. Arnold, M. Kugelmas, M. R. Bashir, et al. “NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients.” In Journal of Hepatology, 66:S92–93. Elsevier BV, 2017. https://doi.org/10.1016/s0168-8278(17)30448-8.Full Text
-
Ratziu, V., A. Sanyal, D. Torres, H. Hinrichsen, L. Serfaty, K. Bambha, S. Jayakumar, et al. “Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis.” In Journal of Hepatology, 66:S594–95. Elsevier BV, 2017. https://doi.org/10.1016/s0168-8278(17)31616-1.Full Text
-
Sanyal, A., S. Harrison, V. Ratziu, M. Abdelmalek, A. Diehl, S. Caldwell, M. Shiffman, et al. “Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis.” In Journal of Hepatology, 66:S2–3. Elsevier BV, 2017. https://doi.org/10.1016/s0168-8278(17)30267-2.Full Text
-
Sanyal, Arun J., Vlad Ratziu, Stephen Harrison, Manal F. Abdelmalek, Guruprasad P. Aithal, Juan Caballeria, Sven M. Francque, et al. “Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study Abstracts.” In Hepatology, 64:1118A-1119A. WILEY, 2016.Link to Item
-
Corey, Kathleen E., Katherine P. Yates, Manal F. Abdelmalek, Arun J. Sanyal, Brent A. Tetri, Kris V. Kowdley, Oscar Cummings, James Tonascia, and Naga P. Chalasani. “Longitudinal relationship between changes in liver histology and renal function in adults with NASH: The NASH Clinical Research Network Experience.” In Hepatology, 64:20A-20A. WILEY, 2016.Link to Item
-
Hameed, Bilal, Norah Terrault, Rohit Loomba, Arthur J. McCullough, Manal F. Abdelmalek, Kris V. Kowdley, Brent A. Tetri, et al. “Subgroup Analysis Comparing Obeticholic Acid versus Placebo for Fibrosis Improvement: a Post-hoc Analysis of the FLINT Trial.” In Hepatology, 64:541A-542A. WILEY, 2016.Link to Item
-
Moylan, Cynthia A., Kara J. Wegermann, Ricardo G. Henao, Susan K. Murphy, Anna Mae Diehl, and Manal F. Abdelmalek. “BCAT1 Is Associated with Clinical Decompensation in Nonalcoholic Fatty Liver Disease: a Pilot Study.” In American Journal of Gastroenterology, 111:S381–S381. Ovid Technologies (Wolters Kluwer Health), 2016. https://doi.org/10.14309/00000434-201610001-00871.Full Text
-
Patel, Yuval A., Ricardo Henao, Cynthia A. Moylan, Cynthia D. Guy, Dawn L. Piercy, Anna Mae Diehl, and Manal F. Abdelmalek. “Vitamin D is Not Associated with Histologic Severity in NAFLD: Results of a Paired Clinical and Hepatic Gene Expression Profile Analysis.” In Hepatology, 64:577A-577A. WILEY, 2016.Link to Item
-
Suzuki, Ayako, Horace J. Spencer, Cynthia A. Moylan, Jonathan A. Dranoff, Manal F. Abdelmalek, Cynthia D. Guy, and Anna Mae Diehl. “Hepatic estrogen transcriptional activity and estrogen receptor a gene expression are negatively correlated with fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD).” In Hepatology, 64:105A-105A. WILEY, 2016.Link to Item
-
Vuppalanchi, Raj, Manal F. Abdelmalek, Eric Lawitz, Peter G. Traber, Adam E. Allgood, Stephen A. Harrison, Zachary D. Goodman, Naga P. Chalasani, and Guadalupe Garcia-Tsao. “Vibration-Controlled Transient Elastography (VCTE) is Useful in Identifying Clinically Significant Portal Hypertension in Patients with NASH Cirrhosis.” In Hepatology, 64:844A-845A. WILEY, 2016.Link to Item
-
Wegermann, Kara, Ricardo Henao, Yiping Pan, Anna Mae Diehl, Manal F. Abdelmalek, and Cynthia A. Moylan. “BCAT1 is Associated with Clinical Decompensation in NAFLD: A Pilot Study.” In Hepatology, 64:577A-577A. WILEY, 2016.Link to Item
-
Kowdley, Kris V., Manal F. Abdelmalek, Arthur McCullough, Rohit Loomba, Bilal Hameed, Naga P. Chalasani, Brent Neuschwander-Tetri, et al. “Mo1557 Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements With Obeticholic Acid.” In Gastroenterology, 150:S1144–S1144. Elsevier BV, 2016. https://doi.org/10.1016/s0016-5085(16)33861-6.Full Text
-
Kowdley, K. V., M. F. Abdelmalek, A. J. McCullough, R. Loomba, B. Hameed, N. P. Chalasani, B. A. Neuschwander-Tetri, et al. “Evaluation of Effects of Concomitant Medications for Non-Alcoholic Steatohepatitis and Associated Comorbidities on Histological Improvements with Obeticholic Acid.” In Journal of Hepatology, 64:S487–88. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)00832-1.Full Text
-
Sanyal, A., Z. Goodman, S. Harrison, D. C. Rockey, A. M. Diehl, S. Caldwell, M. L. Shiffman, et al. “Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis.” In Journal of Hepatology, 64:S251–S251. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)00267-1.Full Text
-
Abdelmalek, Manal F., Kris V. Kowdley, Norah Terrault, Brent A. Neuschwander-Tetri, Arun J. Sanyal, Rohit Loomba, Xiaohong Yan, Reshma Shringarpure, David Shapiro, and Arthur J. McCullough. “Effect of biopsy length on histological response assessment in NASH trials: A secondary analysis of FLINT Trial.” In Hepatology, 62:1256A-1257A. WILEY-BLACKWELL, 2015.Link to Item
-
Bosch, Jaime, Vlad Ratziu, Don C. Rockey, Reem H. Ghalib, Paul J. Thuluvath, Ingolf Schiefke, Steven L. Flamm, et al. “Correlation between noninvasive markers of fibrosis and the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:578A-578A. WILEY-BLACKWELL, 2015.Link to Item
-
Chalasani, Naga P., Rohit Loomba, Norah Terrault, Arthur J. McCullough, Manal F. Abdelmalek, Kris V. Kowdley, Brent A. Neuschwander-Tetri, et al. “Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial.” In Hepatology, 62:332A-333A. WILEY-BLACKWELL, 2015.Link to Item
-
Goodman, Zachary D., Lakshmi Alaparthi, Fanny Monge, Keyur Patel, Rohit Loomba, Stephen H. Caldwell, Eric Lawitz, et al. “Correlations between hepatic morphometric collagen content, histologic fibrosis staging, and serum markers in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:906A-906A. WILEY-BLACKWELL, 2015.Link to Item
-
Harrison, Stephen A., Arun J. Sanyal, Sven M. Francque, Pierre Bedossa, Lawrence Serfaty, Manuel Romero-Gomez, Paul Cales, et al. “Beneficial effects of the dual PPAR alpha-delta agonist, GFT505, on hepatic and cardiometabolic markers in adult NASH patients.” In Hepatology, 62:291A-292A. WILEY-BLACKWELL, 2015.Link to Item
-
Harrison, Stephen A., Zachary D. Goodman, Vlad Ratziu, Rohit Loomba, Anna Mae Diehl, Eric Lawitz, Holger Hinrichsen, et al. “Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:910A-910A. WILEY-BLACKWELL, 2015.Link to Item
-
Hasanaliyeva, Nigar, Keyur Patel, Cynthia D. Guy, Hans J. Gruss, Robert Streilein, Russell Hall, Anna Mae Diehl, and Manal F. Abdelmalek. “IL-8 and MCP1 are Independently Associated with Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.” In Hepatology, 62:1265A-1265A. WILEY-BLACKWELL, 2015.Link to Item
-
Henao, Ricardo, Nigar Hasanaliyeva, Lauren N. Bell, Jacob Wulff, Regis Perichon, Cynthia A. Moylan, James T. Lu, Cynthia D. Guy, Anna Mae Diehl, and Manal F. Abdelmalek. “Plasma Metabolomic Profiles Predict Advanced Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.” In Hepatology, 62:290A-291A. WILEY-BLACKWELL, 2015.Link to Item
-
Loomba, Rohit, Arun J. Sanyal, Kris V. Kowdley, Norah Terrault, Naga P. Chalasani, Manal F. Abdelmalek, Arthur J. McCullough, et al. “Predictors of improvement in NAFLD Activity Score to obeticholic acid: A secondary analysis of FLINT Trial.” In Hepatology, 62:1257A-1257A. WILEY-BLACKWELL, 2015.Link to Item
-
Moylan, Cynthia A., Susan K. Murphy, Carole Grenier, Manal F. Abdelmalek, and Anna Mae Diehl. “DNA Methylation Profiles of Fibrosis-Associated Gene in Blood Reflects Liver Fibrosis Severity in Human Nonalcoholic Fatty Liver Disease.” In Hepatology, 62:648A-649A. WILEY-BLACKWELL, 2015.Link to Item
-
Ratziu, Vlad, Arun J. Sanyal, Rohit Loomba, Stephen H. Caldwell, Reem H. Ghalib, Dawn M. Torres, Arthur J. McCullough, et al. “Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:1298A-1299A. WILEY-BLACKWELL, 2015.Link to Item
-
Ratziu, Vlad, Stephen A. Harrison, Sven M. Francque, Pierre Bedossa, Lawrence Serfaty, Manuel Romero-Gomez, Paul Cales, et al. “An international, phase 2 randomized controlled trial of the dual PPAR alpha-delta agonist GFT505 in adult patients with NASH.” In Hepatology, 62:262A-263A. WILEY-BLACKWELL, 2015.Link to Item
-
Sanyal, Arun J., Stephen A. Harrison, Sven M. Francque, Pierre Bedossa, Lawrence Serfaty, Manuel Romero-Gomez, Paul Cales, et al. “The hepatic and extra-hepatic profile of resolution of steatohepatitis induced by GFT-505.” In Hepatology, 62:1252A-1252A. WILEY-BLACKWELL, 2015.Link to Item
-
Sanyal, Arun J., Zachary D. Goodman, Manal F. Abdelmalek, Stephen A. Harrison, Don C. Rockey, Anna Mae Diehl, Stephen H. Caldwell, et al. “Clinical and histologic correlates of the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:577A-577A. WILEY-BLACKWELL, 2015.Link to Item
-
Vuppalanchi, Raj, Mohammad S. Siddiqui, Erin K. Hallinan, Manal F. Abdelmalek, Brent A. Neuschwander-Tetri, Rohit Loomba, Kris V. Kowdley, et al. “Transient Elastography is Feasible with High Success Rate for Evaluation of Non-Alcoholic Fatty Liver Disease (NAFLD) in a Multicenter Setting.” In Hepatology, 62:1290A-1290A. WILEY-BLACKWELL, 2015.Link to Item
-
Zhu, Ruixin, Susan S. Baker, Cynthia A. Moylan, Manal F. Abdelmalek, Cynthia D. Guy, Fausto Zamboni, Dingfeng Wu, et al. “Systematic Analysis of NAFLD Transcriptome Revealed Elevated Expression of Alcohol Metabolizing Genes in Mild and Severe NAFLD Livers.” In Gastroenterology, 148:S1054–S1054. W B SAUNDERS CO-ELSEVIER INC, 2015.Link to Item
-
Kochhar, Sweta, Manal F. Abdelmalek, Cynthia D. Guy, Dawn Piercy, Yiping Pan, Anna Mae Diehl, and Ayako Suzuki. “Associations of Sleep Duration and Sleep Quality With Clinical and Histologic Features of Nonalcoholic Fatty Liver Disease (NAFLD).” In Gastroenterology, 146:S931–S931. W B SAUNDERS CO-ELSEVIER INC, 2014.Link to Item
-
Yang, Ju Dong, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Katherine P. Yates, Aynur Unalp, Joel E. Lavine, Anna Mae Diehl, and Ayako Suzuki. “Associations of Sex and Menopause With Histologic Severity of Necroinflammation and Portal Inflammation Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD).” In Gastroenterology, 146:S945–S945. W B SAUNDERS CO-ELSEVIER INC, 2014.Link to Item
-
Yang, Ju Dong, Manal F. Abdelmalek, Herbert Pang, Cynthia D. Guy, Alastair D. Smith, Anna Mae Diehl, and Ayako Suzuki. “Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.” In Hepatology, 59:1406–14, 2014. https://doi.org/10.1002/hep.26761.Full Text Link to Item
-
Bohinc, Brittany, Gregory A. Michelotti, Guanhua Xie, Herbert Pang, Ayako Suzuki, Cynthia D. Guy, Dawn L. Piercy, et al. “Repair-related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism.” In Hepatology, 60:411A-412A. WILEY-BLACKWELL, 2014.Link to Item
-
Deng, Y., M. L. Palmeri, N. C. Rouze, S. J. Rosenzweig, M. F. Abdelmalek, and K. R. Nightingale. “Analyzing the impact of increasing Mechanical Index (MI) and energy deposition on shear wave speed (SWS) reconstruction in human liver.” In Ieee International Ultrasonics Symposium, Ius, 719–22, 2014. https://doi.org/10.1109/ULTSYM.2014.0177.Full Text
-
Klair, Jagpal S., Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Katherine P. Yates, Aynur Unalp-Arida, et al. “Risk of severe fibrosis is associated with age at menopause in nonalcoholic fatty liver disease (NAFLD).” In Hepatology, 60:621A-621A. WILEY-BLACKWELL, 2014.Link to Item
-
Urban, Thomas J., Cynthia A. Moylan, Matthew Rein, Manal F. Abdelmalek, David B. Goldstein, and Anna Mae Diehl. “Whole Exome Sequencing of Extreme Phenotypes of NAFLD Identifies Potential Genetic Risk Factors for Advanced Hepatic Fibrosis.” In Hepatology, 60:744A-744A. WILEY-BLACKWELL, 2014.Link to Item
-
Guy, Cynthia D., Ayako Suzuki, Manal F. Abdelmalek, James Burchette, and Anna Mae Diehl. “Hedgehog Pathway Targeted by Vitamin E Therapy in NASH.” In Hepatology, 58:249A-249A. WILEY-BLACKWELL, 2013.Link to Item
-
Garrett, Melanie E., Cynthia A. Moylan, Jason Gibson, Hyuna Yang, Herbert Pang, Andrew Dellinger, Ayako Suzuki, et al. “Expression QTL analysis of a gene expression signature which predicts advanced non-alcoholic fatty liver disease.” In Hepatology, 56:267A-268A. WILEY-BLACKWELL, 2012.Link to Item
-
Jones, Lisa, Dawn Piercy, Susanna Naggie, and Manal Abdelmalek. “Drug-Induced Idiopathic Portal Hypertension Mimicking “Cryptogenic” Cirrhosis in a HIV Patient.” In American Journal of Gastroenterology, 107:S426–S426. Ovid Technologies (Wolters Kluwer Health), 2012. https://doi.org/10.14309/00000434-201210001-01053.Full Text
-
Suzuki, Ayako, Cynthia D. Guy, Herbert Pang, Alastair D. Smith, Anna Mae Diehl, and Manal F. Abdelmalek. “Impact of Gender and Menopause on Histologic Severity of Inflammation and Injury in patients with Nonalcoholic Fatty Liver Disease.” In Hepatology, 56:901A-901A. WILEY-BLACKWELL, 2012.Link to Item
-
Moylan, Cynthia A., Hyuna Yang, Herbert Pang, Andrew Dellinger, Ayako Suzuki, Hans L. Tillmann, Cynthia D. Guy, et al. “Epigenetic Regulation of Gene Expression in NAFLD.” In Gastroenterology, 142:S929–S929. W B SAUNDERS CO-ELSEVIER INC, 2012.Link to Item
-
Corbin, Karen D., Melanie D. Spencer, Kerry-Ann da Costa, Wei Sha, Manal F. Abdelmalek, Yiping Pan, Ayako Suzuki, et al. “Genotype-based hierarchical clustering reveals a panel of polymorphisms in one carbon metabolism that are associated with obesity.” In Faseb Journal, Vol. 26, 2012.Link to Item
-
Shah, Ketan K., Ayako Suzuki, Jeffrey B. Schwimmer, Aynur Unalp, Cynthia D. Guy, Jean P. Molleston, Peter F. Whitington, Richard Johnson, Anna Mae Diehl, and Manal F. Abdelmalek. “DOSE DEPENDENT ASSOCIATION OF FRUCTOSE CONSUMPTION WITH HYPERURICEMIA AND INSULIN RESISTANCE IN CHILDREN WITH NAFLD.” In Hepatology, 54:1116A-1116A. WILEY-BLACKWELL, 2011.Link to Item
-
Moylan, Cynthia A., Andrew Dellinger, Herbert Pang, Ayako Suzuki, Hans L. Tillmann, Daniel Hampton, Yuping Chen, et al. “Modest Alcohol Consumption Attenuates Expression of Fibrosis-Associated Genes in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD).” In Gastroenterology, 140:S914–15. W B SAUNDERS CO-ELSEVIER INC, 2011.Link to Item
-
Zdanowicz, Marzena, Ayako Suzuki, Cynthia D. Guy, Jeffrey Schwimmer, Manal F. Abdelmalek, Joel E. Lavine, and Anna Mae Diehl. “Hedgehog Pathway Activation is Associated With Advanced Fibrosis in Pediatric NAFLD.” In Gastroenterology, 140:S987–S987. W B SAUNDERS CO-ELSEVIER INC, 2011.Link to Item
-
Corbin, Karen D., Kerry-Ann da Costa, Wei Sha, Manal F. Abdelmalek, Anna Mae Diehl, and Steven H. Zeisel. “Single nucleotide polymorphisms affecting phosphatidylcholine transport are associated with obesity.” In Faseb Journal, Vol. 25. FEDERATION AMER SOC EXP BIOL, 2011.Link to Item
-
Tillmann, H., A. Suzuki, H. Pang, A. Dellinger, C. D. Guy, C. A. Moylan, D. Piercy, et al. “869 COFFEE CONSUMPTION INCREASES HEPATIC EXPRESSION OF CYTOCHROME P450S AND SIGNIFICANTLY REDUCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD).” In Journal of Hepatology, 54:S346–47. Elsevier BV, 2011. https://doi.org/10.1016/s0168-8278(11)60871-4.Full Text
-
Abdelmalek, Manal F., Ayako Suzuki, Silke Schmidt, Jacqueline Rimmler, Aynur Unalp, Cynthia D. Guy, Richard Johnson, Michael A. Hauser, and Anna Mae Diehl. “FRUCTOKINASE POLYMORPHISMS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE ARE ASSOCIATED WITH DECREASED URIC ACID AND THE PRESENCE OF HEPATIC FIBROSIS.” In Hepatology, 52:644A-645A. WILEY-BLACKWELL, 2010.Link to Item
-
Abdelmalek, Manal, Ayako Suzuki, Cynthia Guy, Alastair Smith, Babatunde Adeyefa, YiPing Pan, Melissa Smith, and Anna Mae Diehl. “Statin Therapy Decreases Risk of Hepatic Steatosis and Lobular Inflammation in Patients with Nonalcoholic Fatty Liver Disease.” In American Journal of Gastroenterology, 105:S116–S116. Ovid Technologies (Wolters Kluwer Health), 2010. https://doi.org/10.14309/00000434-201010001-00313.Full Text
-
Moylan, Cynthia A., Manal F. Abdelmalek, Herbert Pang, Andrew Dellinger, Steve S. Choi, Alessia Omenetti, Yuping Chen, et al. “SIGNALS FROM THE FIBROTIC LIVER IN PATIENTS WITH NAFLD MAY PROMOTE DIABETES AND OBESITY.” In Hepatology, 52:1049A-1050A. WILEY-BLACKWELL, 2010.Link to Item
-
Moylan, Cynthia A., Steve S. Choi, Andrew Dellinger, Herbert Pang, Manal F. Abdelmalek, Daniel Hampton, Yuping Chen, et al. “CONSERVED GENE EXPRESSION PATTERNS IN MYOFIBROBLASTIC MURINE AND HUMAN HEPATIC STELLATE CELLS AND NAFLD PATIENTS WITH LIVER FIBROSIS COMPATIBLE WITH EPITHELIAL-TO-MESENCHYMAL LIKE TRANSITION.” In Hepatology, 52:1286A-1287A. WILEY-BLACKWELL, 2010.Link to Item
-
Piercy, Dawn L., Ayako Suzuki, Jing Feng, Yiping Pan, Cynthia D. Guy, Anna Mae Diehl, Ambrose A. Chiang, and Manal F. Abdelmalek. “OBSTRUCTIVE SLEEP APNEA WORSENS HEPATIC INFLAMMATION AND FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.” In Hepatology, 52:631A-631A. WILEY-BLACKWELL, 2010.Link to Item
-
Suzuki, Ayako, Martin Binks, Alessia Omenetti, Cynthia D. Guy, Aurora D. Pryor, Yiping Pan, Melissa M. Smith, Anna Mae Diehl, and Manal F. Abdelmalek. “DEPRESSION AND ANXIETY SCORES ARE INDEPENDENTLY ASSOCIATED WITH HISTOLOGIC SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.” In Hepatology, 52:626A-626A. WILEY-BLACKWELL, 2010.Link to Item
-
Abdelmalek, Manal F., Mariana Lazo, Susanne Bonekamp, Anna Mae Diehl, and Jeanne M. Clark. “INCREASED DIETARY FRUCTOSE IMPAIRS HEPATIC ATP HOMEOSTASIS IN NAFLD.” In Hepatology, 50:777A-777A. JOHN WILEY & SONS INC, 2009.Link to Item
-
Suzuki, Ayako, Cynthia D. Guy, Alastair D. Smith, Eric J. DeMaria, Yiping Pan, Melissa M. Smith, Anna Mae Diehl, and Manal F. Abdelmalek. “GENDER AND HORMONAL STATUS ARE ASSOCIATED WITH SEVERITY OF HISTOLOGIC FEATURES AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE.” In Hepatology, 50:772A-773A. JOHN WILEY & SONS INC, 2009.Link to Item
-
Wang, Michael, Mark Palmeri, Ned Rouze, Veronica Rotemberg, Barry Moser, Cynthia D. Guy, Anna Mae Diehl, Manal F. Abdelmalek, and Kathryn Nightingale. “NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS WITH QUANTITATIVE ACOUSTIC RADIATION FORCE METHODS.” In Hepatology, 50:743A-744A. JOHN WILEY & SONS INC, 2009.Link to Item
-
Suzuki, Ayako, Manal F. Abdelmalek, Cynthia D. Guy, Jeffrey Schwimmer, Joel E. Lavine, A. O. Scheimann, and Anna Mae Diehl. “Sexual Development and Its Influence On Regional Anthropometric Measures and Histologic Features Among Pediatric Patients with NAFLD.” In Gastroenterology, 136:A845–A845. W B SAUNDERS CO-ELSEVIER INC, 2009.Link to Item
-
Abdelmalek, Manal F., Keith D. Lindor, Matthew C. Cave, Keith C. Falkner, Rehan Khan, and Craig J. McClain. “HIGH-DOSE BETAINE TREATMENT DOES NOT POSITIVELY INFLUENCE SECOND HIT MECHANISMS IN NASH.” In Hepatology, 48:817A-817A. JOHN WILEY & SONS INC, 2008.Link to Item
-
Jung, Youngmi, Cynthia D. Guy, Liu Yang, Manal F. Abdelmalek, and Anna Mae Diehl. “PROGRESSIVE HEDGEHOG PATHWAY ACTIVATION ACCOMPANIES THE DUCTULAR REACTION DURING NAFLD PROGRESSION IN MICE AND HUMANS.” In Hepatology, 48:829A-829A. JOHN WILEY & SONS INC, 2008.Link to Item
-
Suzuki, Ayako, Manal F. Abdelmalek, Cynthia D. Guy, and Anna Mae Diehl. “GENDER-SPECIFIC ASSOCIATIONS BETWEEN REGIONAL ANTHROPOMETRIC MEASURES AND HEPATIC FIBROSIS IN PATIENTS WITH NAFLD.” In Hepatology, 48:804A-804A. JOHN WILEY & SONS INC, 2008.Link to Item
-
Abdelmalek, Manal F., Schuyler O. Sanderson, Paul Angulo, Chen Liu, Joy Peter, Jill Keach, and Keith D. Lindor. “Betaine for treatment of nonalcoholic steatohepatitis: Results of a randomized placebo controlled study.” In Hepatology, 44:200A-201A. JOHN WILEY & SONS INC, 2006.Link to Item
-
Abdelmalek, Manal F., Paul Angulo, Roberta A. Jorgensenh, Pamela B. Sylvestre, and Keith D. Lindor. “Betaine for the treatment of nonalcoholic steatohepatitis: A promising new agent.” In Gastroenterology, 118:A973–A973. Elsevier BV, 2000. https://doi.org/10.1016/s0016-5085(00)86034-5.Full Text
-
Diehl, A. M., and M. F. Abdelmalik. “Nash: Bench to bedside - lessons from animal Models,” 3–15. Springer Netherlands, n.d. https://doi.org/10.1007/978-1-4020-6523-1_1.Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.